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Background: Hip fracture in the elderly has high morbidity and mortality.
Thromboembolic disease (TED) is one potential explanation for increased morbidity
and mortality in hip fracture patients. National guidelines have recommended low
molecular weight heparin or aspirin for thromboprophylaxis (TP) following hip fracture.
While these treatments reduce clinical and radiological incidence/prevalence of TED,
the Cochrane review of TP in hip fracture patients (2002), was unable to demonstrate a
survival benefit with different types of TP.
Aim: To explore the effect of different types of TP in hip fracture patients after
adjusting for cofactors and comorbidities.
Data sources: Prospectively collected Scottish Hip Fracture Audit (SHFA) data, linked
to routinely collected Scottish Morbidity Records (SMR) providing information about
hospital discharges, mortality records and cancer registry data.
Participants: 8470 patients aged 60 years and over admitted to NHS hospitals in
Scotland with hip fracture (1998 to 2003).
Methods: Multivariate analysis (Cox proportional hazards regression analysis),
adjusting for SHFA variables (including age, sex, residence pre-fracture, American
Society of Anesthesiologists grade, delay to surgery for medical reasons, hospital, and
type of TP received), and SMR variables (including the Scottish Index of Multiple
Deprivation, number of hospital inpatient episodes in the five years prior to hip fracture,
previous diagnoses with cardiovascular disease or respiratory disease, or cancer
registration).
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Main results: The mortality rate in the year following hip fracture was 30% (95% CI
29 to 31%). Clinically identified TED was uncommon in the year following hip
fracture with 1.4% (95% CI 1.2 to 1.7%) patients recorded as having an inpatient
episode with a primary diagnosis of TED and 0.3% (95% 0.2 to 0.4%) patients recorded
with TED as the primary cause of death. There was evidence of reduced mortality in
patients documented as receiving aspirin (hazard ratio 0.86; 95% CI 0.78 to 0.95) or
graduated elasticated compression (GEC) stockings (HR 0.88; 95% CI 0.80 to 0.97), but
there was no statistically significant effect on combined admissions/ deaths from TED
or coronary artery disease with aspirin (HR 1.07; 95% CI 0.83 to 1.38) or GEC
stockings (HR 1.11; 95% CI 0.90 to 1.37). Heparin did not have a statistically
significant influence on outcomes.
Main conclusions: The findings of this study suggest that aspirin and GEC stockings
may be beneficial following hip fracture, but the findings may be explained by residual
confounding, and a randomised controlled trial of GEC stockings and/ or aspirin in
elderly hip fracture patients is warranted.
Key words: Thromboembolic disease, thromboprophylaxis, hip fracture, comorbidities.
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Hip fracture is an orthopaedic emergency. Figure 1.1 shows the site of different types
of hip fracture. Compared with an age and sex matched population, the excess mortality
for hip fracture patients has been estimated at 10% to 20% in the first year following the
fracture, with most of the excess mortality occurring in the first 6 months after the
fracture1.
Hip fracture is common. The cumulative lifetime risk of hip fracture in economically
advanced countries is estimated at 15% among women and 5% among men2. The
majority of fractures occur as a result of falls in frail, elderly patients with osteoporosis.
Hip fracture often leads to a decline in functional status, deterioration in mobility and
greater dependence on carers. Hospital admissions for hip fracture can be prolonged
and care involves the input of up to 50 health professionals3.
Hip fracture is therefore expensive and care is complex. For these reasons hip fracture
has been chosen as a "tracer condition" by NHS Quality Improvement Scotland, by
which to examine patient journeys in older people in more detail4. The Scottish Hip
Fracture Audit (SHFA) has collected data about quality of care for up to half of all hip
fracture patients in Scotland since 1992 and this allows the detailed study of outcomes
of care of hip fracture patients in Scotland.
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1.2 Epidemiology of hip fracture in Scotland
The epidemiology of hip fracture in Scotland up to 1998 is summarised in the 2002
Scottish Intercollegiate Guidelines Network (SIGN) guideline for hip fracture3.
Between 1982 and 1998 the number of hip fractures per year in Scotland in people aged
55 years and over rose from 4,000 to 5,700. This increase was not wholly attributable
to the increasing age of the Scottish population as the age-standardised risk rose during
the same period from 165 to 205 per 100,000 men and 500 to 593 per 100,000 women
aged 55 years and over .
1.3 Thromboembolic disease (TED) in hip fracture patients
Thromboembolic disease (TED) is a potentially important cause of morbidity and
mortality following hip fracture and includes deep vein thrombosis (DVT) and
pulmonary embolism (PE). In studies of hip fracture patients who did not receive
thromboprophylaxis but underwent radiological testing, DVT was identified in 40 to
60% of patients and PE in 3 to 28% of patients5.
Over 150 years ago Virchow described a triad of factors that contribute to the
pathogenesis of TED - vascular endothelial damage, stasis of blood flow, and
hypercoagulability of blood6'7. Each of these factors is likely to have a role in the
pathogenesis of TED in hip fracture patients. Hip fracture patients are often socially
isolated (elderly, living alone) and may live in damp and poorly heated houses. Many
hip fractures occur in the home. Following hip fracture, patients can lie for hours or
days before being taken to hospital, and they can be dehydrated and hypothermic,
contributing to venous stasis and abnormal clotting8. The trauma of the fracture and the
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body's response to this trauma leads to endothelial damage and changes in clotting, and
these are exacerbated by surgery and immobility during the recovery period which
further contribute to venous stasis and abnormal clotting9. Although the precise
pathophysiological mechanism through which thrombus formation occurs is not yet
fully understood, it is likely to involve platelets, clotting factors, and cellular
interactions with the endothelium and once the thrombus has developed there is a
continual process of organisation of thrombus, with embolism occurring in some
patients10. Thrombus formation appears to be related to both the site of the fracture and
the timing of surgery as around 75% of DVT occur in the operated leg, and the peak
incidence of TED occurs during the first hours and days following surgery1'. Around
one third of patients with DVT are thought to develop chronic problems (post-
thrombotic syndrome) with pain, pruritis and oedema of the affected site12. Various
aspects of hip fracture management may reduce the burden of TED following hip
fracture, including thromboprophylaxis (section 1.4), reducing the delay to surgery,
early mobilisation and spinal anaesthesia3.
The clinical relevance of DVT following hip fracture depends on the method of
diagnosis and the site of the clot. Studies based on radiological tests typically identify a
higher rate of TED than studies based on clinical findings, but radiologically identified
DVT may not be clinically important. In one review, 46% of hip fracture patients had
radiological evidence of DVT, 19% had radiological evidence of proximal DVT (which
is more likely to lead to PE), and 7% had clinical DVT13. PE may also go undetected
and deaths may be attributed to other causes, so clinical studies may underestimate the
true incidence of TED following hip fracture. However it is not ethical to subject
13
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patients routinely to the invasive radiological tests required for diagnosis of PE.
Historically, using data from autopsy based studies, PE appears to have been under-
reported following hip fracture14' 5, and more recent autopsy studies have also shown a
high prevalence of PE following hip fracture although these findings may at least partly
be explained by selection of patients for autopsy who are more likely to have died from
a PE due to sudden death or death soon after a surgical procedure16.
1.4 Thromboprophylaxis in hip fracture patients
Thromboprophylaxis is a term used for a group of mechanical and pharmacological
treatments that can reduce TED. Examples of mechanical thromboprophylaxis include
graduated elasticated compression (GEC) stockings and foot pumps. Examples of
chemical thromboprophylaxis include heparin, aspirin and warfarin. Successive SIGN
guidelines for hip fracture have recommended the use of low molecular weight heparin
17 •• «« ••
(LMWH) or aspirin . GEC stockings increase mean blood velocity in leg veins and
reduce venous stasis18 and have been shown to be effective in preventing TED after
1T • •
major surgery , but their role after hip fracture has not been widely studied.
Trial evidence supporting the use of thromboprophylaxis following hip fracture is
limited. The most recent Cochrane review published on thromboprophylaxis in hip
fracture patients noted that, although there is evidence for reduction in TED following
hip fracture with heparin, there is little evidence for a reduction in mortality19. The
results of the Pulmonary Embolism Prevention (PEP) trial suggest that aspirin may also
provide protection against fatal pulmonary embolism following hip fracture, but a
similar effect on other vascular deaths or all-cause mortality was not demonstrated20.
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Nonetheless, aspirin has an established role in the primary and secondary prevention of
cardiovascular disease (CVD)21 and may also protect against breast22 and colorectal
23 • • • • •
cancer , all of which are common causes of morbidity and mortality in elderly patients
at risk of hip fracture.
Thromboprophylaxis may also have harmful effects. For example, chemical
thromboprophylaxis may increase the risk of haemorrhage or peptic ulcer disease.
Understanding the balance between reducing TED and increasing haemorrhagic events
is important in understanding the influence of thromboprophylaxis on morbidity and
mortality following hip fracture. As noted by the THRIFT consensus group, if "the risk
of adverse effects from bleeding has been underestimated, as many surgeons suspect, or
if the risk of thromboembolic events were shown to be lower than the lower confidence




1.5 Rationale for this study
The previous sections have highlighted some of the questions surrounding hip fracture,
TED and thromboprophylaxis. The first stage of this study is therefore to perform a
literature review, to explore the available data on these issues systematically. In light of
the challenges in diagnosing TED, the literature review identifies descriptive studies to
explore the epidemiology of clinically relevant TED following hip fracture. In order to
understand the factors that may influence mortality following hip fracture, the literature
review then identifies descriptive studies that explore the influence of patient factors,
medical comorbidities and social influences in hip fracture patients. Finally, the
literature about thromboprophylaxis in hip fracture is reviewed to provide an update to
evidence from the most recent Cochrane review on this topic19. The findings of the
literature review are used to inform the design of the rest of the study.
Evidence about the potential impact of medical, surgical and anaesthetic advances in the
management of hip fracture is explored using Scottish Morbidity Records (SMR) data
available for the period 1986 to 2003. SMR data are collected routinely following
hospital discharge and have been linked previously to other hospital discharge data,
death records, cancer registry data and the Scottish Index of Multiple Deprivation
(SIMD). The modern era of hip fracture treatment, marked by the publication of the first
SIGN guideline in 1997, might be expected to have led to improvements in hip fracture
outcome. The age and comorbidities of patients at the time of hip fracture have,
however, increased over time25, and these influences need to be considered in the
analysis. SMR data are therefore used to adjust outcomes for age, gender, number and
16
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type of inpatient episodes during the 5 years prior to hip fracture (as a proxy for
comorbidity), and deprivation category. These variables provide information about the
potential impact of evidence-based treatment, including thromboprophylaxis, on hip
fracture outcomes.
This study then focuses on the influence of thromboprophylaxis on all-cause mortality
and other events following hip fracture. The study uses data collected between 1998
and 2003 from two Scottish databases, providing information about previous medical
history, thromboprophylaxis during the hip fracture admission and outcomes following
hip fracture. The two databases that have been linked to produce this database are the
SHFA database, which provides information about thromboprophylaxis and other
measures of quality of care, and the SMR database (see above).
In contrast to many other published research studies on this topic, this study uses data
from a large number of patients, and has not excluded patients who are very ill or very
old, so the findings would be expected to be more relevant to the general hip fracture
population than some other epidemiological studies of selected patient groups and the
selected groups of patients normally enrolled in clinical trials. As there is detailed
information about patients before, during and after hip fracture it is possible to adjust
for differences in age, gender and comorbidities that may influence the findings.
17
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1.6 Aims and objectives
This work examines the influence of thromboprophylaxis on death and TED or CVD
following hip fracture after adjusting for potential confounding factors. The objectives
are listed in the section explaining the rationale in each of the next four chapters.
1.7 Research questions
The following research questions form the basis of this study.
1) What is the likely burden of TED following hip fracture?
2) Did outcomes in hip fracture patients alter following the launch of the first
national evidence-based guidelines in 1997?
3) Is there evidence of improved survival in hip fracture patients who have
received different types of thromboprophylaxis, and does this relationship
persist after adjusting for cofactors?
4) If a particular type of thromboprophylaxis has an influence on survival, then
is this relationship explained by changes in the incidence of secondary
outcomes following hip fracture (TED, CVD and haemorrhage)?
5) How representative of elderly hip fracture patients in Scotland as a whole are
the sub-set of patients included in this analysis?
18
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1.8 Comparison with earlier work in Scotland
I have previously looked at hip fracture and TED in Scotland for a thesis submitted for
the degree of Masters of Public Health (University of Glasgow, 2002)25. Results
included descriptions of the epidemiology of hip fracture and TED following hip
fracture between 1982 and 1998 using SMR data, and a description of
thromboprophylaxis usage in 2788 patients participating in SHFA in 1998. It was not
possible at that time to link the SMR and SHFA databases together, so only limited
conclusions were possible in that thesis. Additionally, as the national guidelines on hip
fracture were published in 199717 and updated in 20023, these findings may not be
relevant to current practice.
The current study has been made possible by recent improvements in the Scottish data
on hip fracture. SHFA records have now been linked to SMR records providing
longitudinal data for over 18,000 SHFA participants admitted between 1998 and 2003.
Linkage to SMR records has been performed for the 5 years prior to hip fracture and the
year following hip fracture, providing information about previous inpatient episodes,
socio-economic status and subsequent outcomes. The conclusions available from this
new analysis are therefore based on a more detailed analysis of a larger number of





The primary outcome of interest for this study is all-cause mortality in the year
following hip fracture admission. Estimating the sample size required to identify a
statistically significant reduction in mortality with thromboprophylaxis is not
straightforward, because a substantial proportion of patients receive more than one type
of thromboprophylaxis, the proportion of patients receiving thromboprophylaxis varies
by type of treatment, and there are inadequate data from previously published studies to
estimate the likely reduction in mortality with thromboprophylaxis. The estimation of
sample size is therefore based on a series of assumptions.
The findings of previously published studies suggest that heparin has the largest
treatment effect of conventional types of thromboprophylaxis, with a 40% reduction in
radiologically identified TED19 and use of heparin is documented in approximately 50%
of SHFA participants25. With an expected mortality rate of 30% during the year
following hip fracture, and assuming a 10% reduction in mortality with heparin
compared to patients receiving other thromboprophylaxis regimes, the sample size
required to detect a reduction in mortality with heparin is estimated at 3570 patients per
9 f\
study limb (5% significance level, 80% power) . There are data available for 18,000
patients in this analysis. Therefore this study is likely to be adequately powered for
heparin. However, the sample size for other types of thromboprophylaxis will vary by
the size of the treatment effect (which cannot be quantified using existing evidence) and














The aim of this thesis is to examine the influence of thromboprophylaxis on death and
other outcomes following hip fracture, adjusting for confounding factors. This chapter
reviews the published literature relating to this topic.
2.2 Background
The previous chapter has highlighted the potential importance of TED following hip
fracture. There is considerable uncertainty, however, about the incidence of clinically
apparent TED following hip fracture.
A Cochrane review published in 2002 studied the influence of heparin and mechanical
thromboprophylaxis on outcomes following hip fracture and identified a number of gaps
in the literature. There were few studies identified that looked at the influence of
thromboprophylaxis on mortality following hip fracture, and there were few studies of
the influence of GEC stockings19. This is despite evidence from studies of other types
of major surgery that GEC stockings may reduce TED13. Aspirin, which is the preferred
type of thromboprophylaxis in the most recent SIGN guideline on hip fracture , may
also reduce TED but has not been demonstrated to reduce mortality in hip fracture
90
patients .
There therefore remain a number of unanswered questions, particularly relating to the
influence of different types of thromboprophylaxis on mortality following hip fracture.
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The findings of the literature review described here inform the design of the study
described in subsequent chapters in order to fill gaps in the existing literature.
2.3 Rationale
2.3.1 Objective 1a. To review the published literature to identify the
incidence of thromboembolic disease (TED) following hip fracture
Understanding the epidemiology of clinically apparent, radiologically confirmed TED
following hip fracture is of major importance in this study. The findings will be used to
assess the accuracy of hospital discharge data (chapter 3), and will be used to estimate
the sample size required in the study of the influence of thromboprophylaxis on
secondary outcomes (chapter 5).
2.3.2 Objective 1b. To review the published literature to identify
demographic, medical and social factors that influence mortality
following hip fracture
Chapters 4 and 5 study the influence of different types of thromboprophylaxis on
outcomes following hip fracture. There may, however, be important variation in the
characteristics of patients receiving different types of thromboprophylaxis that could
also influence outcome. The factors that have been shown to be most important in
predicting outcome following hip fracture will be identified from the published
literature. This information will be used to identity relevant variables from routinely
collected hospital discharge data (chapter 3) and SHFA data (chapter 4).
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2.3.3 Objective 1c. To update the findings of previous reviews of
thromboprophylaxis in hip fracture
Papers published since the time of the most recent Cochrane review of
thromboprophylaxis in hip fracture and the SIGN guideline on hip fracture will be
reviewed to examine whether any subsequent trials have demonstrated the superiority of
different types of thromboprophylaxis over placebo on long-term survival following hip
fracture.
2.4 Methods
The literature review was performed in December 2004 and involved the steps shown in
figure 2.1, adapting search strategies from the Cochrane review for thromboprophylaxis
in hip fracture19 using MEDLINE and EMBASE databases (appendix). Additional
references were identified from the bibliographies of key references identified in the
search. Objectives la and lb were explored by reviewing descriptive studies and
objective lc was explored by reviewing randomised controlled trials, using inclusion
and exclusion criteria listed in table 2.1. Figure 2.1 shows the number of studies that
were excluded at each stage to give the final number of papers selected for further study
(n=35). Authors of potentially useful studies of lower limb surgery were contacted with
requests for further information for hip fracture alone. Of the authors contacted,
Barrett27 responded with additional data, and Ollendorf 28 replied but was unable to
provide additional data.
Of the 35 selected papers, 23 provided data relevant to objective la (of which 2
provided additional data for objective lb and 1 provided data for objective lc). These
25
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studies were divided into clinical studies (n=19) and autopsy studies (n=4). An
additional 12 papers provided information about comorbidities (objective lb).
2 Literature review
2.5 Results
2.5.1 Objective 1a: To identify the incidence of clinical DVT and PE
following hip fracture
In total 19 papers that provided information about the incidence of TED following hip
fracture were identified. These included 11 studies where the main aim of the study was
to identify the incidence of TED or other medical complications following hip fracture,
of which 5 studies recruited patients prospectively (table 2.2) and 6 studies collected
data retrospectively (table 2.3). The remaining 8 studies were conducted for other
purposes, but included information about the incidence of TED following hip fracture
(table 2.4). The key studies are described and appraised below.
2.5.1.1 Studies estimating the incidence of TED in the year following hip
fracture
Two papers described TED and other complications in the year following hip fracture
(the follow-up period studied in subsequent chapters).
Gerber et al studied TED in the year following hip fracture, identifying clinical PE in
3.3% (95% confidence intervals (CI) 1.5 to 5.0%) of patients. These data were collected
at patient review four months and one year after hip fracture. This study had a number
of limitations. The study was conducted between 1972 and 1988 and may not therefore
be relevant to current practice. A lower proportion of patients received
thromboprophylaxis than in many other studies (45%). There was no information about




Vajanto et al studied outcomes at around one year of follow up, with 2.1% (95% CI 0.6
to 3.7%) of patients identified with PE and 1.5% (95% CI 0.2 to 2.8%) with DVT
during an average follow-up period of 58 weeks. There was no indication of how many
patients developed both DVT and PE so the overall burden of TED in this study can not
be estimated. Data were collected retrospectively from patient records of patients
admitted with hip fracture between 1990 and 1993. All patients were given LMWE1
before and after surgery. There was no information about the radiological techniques
used to investigate patients with suspected TED. Information was available about other
complications one year after hip fracture, but not mortality30.
2.5.1.2 Large studies of the incidence of TED following hip fracture, using
administrative data
The most precise estimates of the incidence of TED following hip fracture came from
two very large retrospective studies conducted in the United States using administrative
data.
Ollendorf et al used hospital discharge records collected from 220 hospitals between
1998 and 1999, identifying DVT in 0.82% (95% CI 0.7 to 0.9%) of patients and PE in
0.5% (95% CI 0.5 to 0.6%) during the hip fracture admission; overall 1.4% (95% CI 1.2
to 1.5%) of patients developed TED during the hospital admission28.
Barrett et al used Medicare billing information to follow up hip fracture patients
identified in the 5% United States standard sample of the Medicare population between
1986 and 1990, with PE identified in 1.6% (95% CI 1.5 to 1.7%) of patients within 90
97
days of hip fracture .
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While both these studies specifically examined the epidemiology of TED in fracture
patients, both relied on administrative data and there were no data about
thromboprophylaxis usage or methods of radiological confirmation.
2.5.1.3 Studies estimating the overall burden of DVT and PE following hip
fracture
In most papers there was insufficient detail to estimate the overall proportion of patients
with TED. The following studies did however provide some information about the
overall incidence of TED following hip fracture.
Todd et al used prospectively collected East Anglian Audit data to study outcomes
following hip fracture. In common with the findings presented in chapter 4, this study
used the results of a prospective audit based on the Standardised Audit of Hip Fractures
in Europe. Use of chemical thromboprophylaxis was reported in 45% of patients, but
use of mechanical thromboprophylaxis was not described. Data collected from hospital
records showed that 5.3% (95% CI 3.5 to 7.2%) of patients were diagnosed with
"postoperative thrombosis", but there were no details about radiological testing or the
29
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anatomical distribution of thrombus*. 2.2% (95% CI 1.0 to 3.5%) of patients developed
fatal PE during the 90 days following hip fracture but it is not clear whether these
patients underwent autopsy*31. Uncertainties about definitions and methodology in this
study make it difficult to compare the findings with other studies.
Lawrence et al retrospectively identified TED in 1.0% (95% CI 0.8 to 1.2%) of patients
during hospital admission, with full details about radiological testing. This estimate
was based on data collected between 1982 and 1993, and information about
thromboprophylaxis was not available32.
Ollendorf et al also provided information about the overall burden of TED (see section
2.5.1.2 above), as did the two studies described in section 2.5.1.4 below.
2.5.1.4 Recent studies focusing on TED and haemorrhagic complications
Few published studies provide detailed information about complications of hip fracture
(and its management) in the modem era ofhip fracture treatment. Two studies provided
*
There were no details about the proportion of these patients who experienced proximal DVT
and/ or PE. It is possible therefore that this estimate included superficial thrombus and distal
DVT which are of less clinical importance.
* The paper states: "Although few patients were identified at postmortem examination as having




recent and detailed information about TED, haemorrhagic complications and use of
thromboprophylaxis following hip fracture.
Thaler et al prospectively studied hip fracture patients admitted between 1997 and 1999,
identifying radiologically confirmed TED in 0.8% (95% CI 0.2 to 1.4%) of patients
during the hospital admission, with no TED deaths recorded. Major haemorrhagic
events# were recorded in 4.7% (95% CI 3.3 to 6.1%) of patients, and one death (0.1%,
95% CI 0 to 0.3%) was recorded as being due to intracerebral haemorrhage. The study
also provided information about the accuracy of clinical diagnosis in detection of TED.
Only 14% of suspected DVT and 50% of suspected PE were confirmed when patients
underwent radiological testing. Younger patients were included in this study which
may have resulted in an underestimate of postoperative complications. However, the
majority of patients were elderly, and a high level of previous medical illness was
documented in the study participants. Consequently, these findings are probably
reasonably representative of the elderly hip fracture population33.
#
Major haemorrhagic events were defined as clinically overt intracranial or retroperitoneal
bleeding unrelated to trauma that led to transfusion of 4 or more units of packed red blood cells
within the first 24 hours of operation, or bleeding at the operative site leading to re-operation for
bleeding and transfusion of 2 or more units.
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Ennis et al looked retrospectively for TED and haemorrhagic complications during the
three months following hip fracture in a group of patients admitted to hospital between
1995 and 1999. Patients received a variety of types of mechanical and chemical
thromboprophylaxis, and 0.6% (95% CI 0.1 to 1.2%) of patients developed TED,
including one fatal PE. In total 0.8% (95% CI 0.2 to 1.3%) of patients had a major
bleeding episode*, including one death (0.1%, 95% CI 0 to 0.3%) from gastrointestinal
bleeding. This study also included some younger patients, but the majority of patients
were elderly and the average age was similar to that expected in a population of elderly
hip fracture patients34.
2.5.1.5 Autopsy studies
Some additional information about the burden of TED is provided in studies reporting
autopsy findings. Table 2.5 summarises the results from the four autopsy studies
identified in the literature search. The majority of data in these studies were collected
more than ten years ago, and some were collected more than 50 years ago, so the
relevance to current practice is not clear. There was considerable heterogeneity between




studies. Depending on the study, between 11.1 and 19.0% of autopsies identified PE as
causing or contributing to death at a maximum of 3 months follow up.
Table 2.6 shows the combined findings of three of the autopsy studies that provided
data about all causes of mortality. PE was the most common thrombotic cause of death
and third most common cause of death overall (only pneumonia and congestive cardiac
failure were more common). Overall 25.7% deaths were attributed to thrombotic events
and 2.8% deaths to haemorrhagic events.
2.5.1.6 Other studies
The remaining studies summarised in tables 2.2 to 2.4 were, typically, smaller studies of
the period of the hip fracture admission. The studies listed in table 2.4 had diverse aims
and methodologies. Many studies had limitations for this particular objective including
incomplete documentation35'36 and a high proportion of drop-outs37. In some studies
there was over representation of particular groups including men37'38, and more
physically able patients39. In one study there was under-representation of patients with a
previous history of TED or haemorrhage37.
2.5.2 Objective 1b: to identify medical and social factors that influence
mortality following hip fracture
Some studies explored the impact of comorbidities on mortality following hip fracture.




Age was an important predictor of mortality31'35'40. Patients aged 85 years and over had
a higher mortality at one year than patients aged under 85 years (hazard ratio 2.7; 95%
CI 1.7-4.4)41. Sex was also an important predictor of mortality with men more likely to
die than women within the first 90 days following hip fracture (odds ratio 2.9; 95% CI
1.5 to 5.4)31.
2.5.2.2 Social circumstances and functional characteristics
Patients who required assistance for basic activities of daily living had a higher
mortality than those who did not require such assistance. In one study, mortality at 90
days was higher for patients with poorer function (odds ratio 1.07 per unit increase in
• •• 1" ^ 1
activities of daily living scale, 95% CI 1.04 to 1.10) . In another study, mortality at
one year was higher in patients who required assistance with activities of daily living
than among those who did not require assistance (hazard ratio 2.4; 95% CI 1.5-3.9)41.
Patients in residential care had higher mortality than other patients at 24 months for
patients aged 50 to 79 years (odds ratio 1.7; 95% CI 1.4 to 2.1), and for patients aged 80
and over (odds ratio 2.7; 95% CI 1.8-4.0)42.




Patients with severe systemic illness prior to fracture (American Society of
Anesthesiologists (ASA) grades 3 or 4+) had higher mortality at one year (hazard ratio
3.9; 95% CI 2.3-6.7)41 a finding that was consistent with other studies43. Cancer
(excluding skin cancer) was an important predictor of mortality at one year (hazard ratio
3.1; 95% CI 1.8-5.4)41 while a prior history of the following conditions increased
adverse outcomes at 30 days following hip fracture: congestive cardiac disease (odds
ratio 32.3; 95% CI 5.4-192.0), angina (odds ratio 25.7; 95% CI 3.6 to 184.0) and
chronic obstructive pulmonary disease (odds ratio 11.1; 95% CI 2.0 to 62.0)44. Prior
CVD was associated with increased mortality at 90 days compared to those with no
history of CVD (odds ratio 2.13; 95% CI 1.25 to 3.64)31. Patients with diabetes had a
higher mortality during the hospital admission than those without diabetes (odds ratio
3.0; 95% CI 1.1 to 8.0) but no difference in mortality was found after one year of follow
* ASA grade documents the level of systemic disease prior to hip fracture: grade 1 = a healthy
patient; grade 2 = a patient with mild systemic illness; grade 3 = a patient with severe systemic
disease that is not incapacitating; grade 4 = a patient with incapacitating systemic disease that
is a constant threat to life; grade 5 = a moribund patient not expected to survive for 24 hours43.
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The medical conditions listed above that had an important influence on mortality appear
to have been relatively common in hip fracture patients. A summary of the prevalence
of these conditions, as derived from the reviewed studies, is shown in table 2.7.
Different studies used different diagnostic groupings, and there is likely to have been
some overlap between some conditions, for example between CVD, CHD and stroke.
2.5.2.4 Quality of care
Other aspects of hip fracture management may also have also influenced outcome.
Operative delay to hip fracture surgery of more than 48 hours had an adverse effect on
outcome (hazard ratio 1.63; 95% CI 1.11 to 2.40) in one study, but surgical delay may
be due either to the patient's condition or hospital factors relating to quality of care and
findings in other studies are contradictory43. Speed of mobilisation following surgery
was identified as an important influence on mortality 90 days post-operatively in a re-
audit of hip fracture care in the East Anglian Audit#.
#
Freeman C, Todd C, Camilleri-Ferrante C, et al. Quality improvement for patients with hip
fracture: experience from a multi-site audit. QuaI Saf Health Care 2002;11:239-245.
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2.5.3 Objective 1c: to update the findings of previous reviews of
thromboprophylaxis in hip fracture
Chapter 1 provided a summary of existing evidence about thromboprophylaxis in hip
fracture patients, including the findings of the most recent Cochrane review on this
topic19 (section 1.4). In the literature search, one randomised controlled trial comparing
thromboprophylaxis with placebo was identified which was published after the most
recent update of the Cochrane review. Eriksson et al showed an apparent protective
effect with fondaparinux (a novel pentasaccharide/ heparinoid) with a 95.9% (87.2 to
99.7%) relative risk reduction in combined clinical and radiological TED during the
first 32 days following hip fracture admission and an 88.8% (95% CI 67.7 to 100%)
relative risk reduction in symptomatic TED37. There were a number of limitations to
this study. The study did not have a true placebo limb, as all patients received open
label LMWH for 6 to 8 days prior to randomisation to fondaparinux or placebo. Overall
42% of those initially recruited were excluded or dropped out of the study. Most
importantly, the primary endpoint included the results of mandatory bilateral
venography in all patients, so the clinical relevance is unclear. In the control limb of the
study, for example, 35% of patients had radiological evidence of DVT, but only 1.8%
had clinical evidence of DVT and 0.9% had clinical evidence of PE. The influence of
fondaparinux on all-cause mortality was not assessed in this study37.
Eriksson et aT s study does not therefore alter the conclusions of the Cochrane review of
thromboprophylaxis in hip fracture, which showed no statistically significant influence
of different types of thromboprophylaxis on mortality19. Indeed the funnel plot of the
studies included in the Cochrane review (figure 2.2) shows evidence of publication bias
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favouring studies that suggested a beneficial effect of heparin, with lower precision
estimates to the left of the pooled estimate, and more precise estimates to the right.
2.6 Discussion
2.6.1 Objective 1a. To identify the incidence of DVT and PE following hip
fracture
There were limited data describing the long-term burden of TED following hip fracture.
The considerable variation in estimates of incidence of TED in different studies
reflected differences in casemix and methodology. Few studies collected data
prospectively and many were studies of the general complications of hip fracture,
providing limited detail about TED, including thromboprophylaxis regimes and/or
radiological tests. The majority of studies used data collected more than ten years ago
and no study of outcomes for the full year after hip fracture included more recently
collected data, so the findings may not reflect current practice, particularly with the
increase in the use of chemical thromboprophylaxis more recently. Acknowledging
these limitations, the incidence of clinically apparent TED in the year following hip
fracture is estimated to be around 3%29'30 (section 2.5.1.1).
TED was relatively common at autopsy. The studies listed in table 2.5 can be divided
into two groups: studies in Scandinavian countries where autopsy was performed in the
majority of patients (over 60%), and studies in English speaking countries where
autopsy is performed infrequently (under 30%, where stated). Scandinavian studies
would be expected therefore to have been more representative of all hip fracture patients
who died following hip fracture, while the studies from English speaking countries may
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be expected to have included more sudden and unexplained deaths, thereby
overestimating the burden of fatal PE (see section 1.3). It is therefore interesting to note
that the proportion of autopsies identifying PE as the cause of death or contributing
factor was high, at between 10-20%, regardless of the autopsy rate. PE therefore
appears to have been a common cause of death in the postoperative period, although it
should be noted that the findings of these studies may not be relevant to current practice
as the data were predominantly collected more than ten years ago, and often many
decades ago, before the widespread use of thromboprophylaxis.
The more recent studies identified for the literature review reveal that there remains a
discrepancy between radiologically diagnosed TED and clinical events. Eriksson et al
identified radiological TED in 35% of patients but clinically apparent TED in less than
37 • •3% . Thaler et al showed that the majority of patients with clinically suspected TED
tested negative on venography and/or spiral CT scan33. This finding may be explained
by the fact that elderly hip fracture patients commonly have a number of other medical
conditions leading to leg swelling and/or chest pain and breathlessness that can be
mistaken for TED. Such misclassification bias is a problem common to all studies of
TED following hip fracture. There is also the possibility that TED may occur silently.
If this is the case then TED may be an important but unsuspected cause of morbidity
and mortality, and thromboprophylaxis would be expected to have an influence on
morbidity and mortality beyond that expected from the observed incidence of TED.
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2.6.2 Objective 1b. To identify medical and social factors that have the
greatest influence on mortality following hip fracture
The findings of the studies exploring the impact of comorbidities and cofactors on
outcomes following hip fracture were plausible, showing higher mortality in older
patients, dependent patients and patients with medical comorbidities. There was
unfortunately no information about smoking status in these studies. There was
considerable heterogeneity in the odds ratios for some medical conditions. Nettleman et
al identified very high odds ratios for a number of medical comorbidities, including an
odds ratio of 32 for patients with congestive cardiac failure44. These findings may be
explained by the fact that the medical comorbidities were identified using records
relating to the hip fracture admission. Events identified during the admission may have
progressed to contribute to the patient's death within that same admission, so these
findings could be biased.
There was also considerable heterogeneity in the prevalence of some medical conditions
in the different studies listed in table 2.7, with an almost ten-fold difference in the
reported prevalence of diabetes and dementia across studies. The wide range of
estimates reflects differences in the design and recruitment to studies, and the age of the
population.
2.6.3 Objective 1c. To update the findings of previous reviews of
thromboprophylaxis in hip fracture
As identified in the most recent Cochrane review of hip fracture and
thromboprophylaxis19 there remains a shortage of adequately powered studies exploring
the effect of thromboprophylaxis on mortality. Results from the one randomised
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controlled trial identified in this literature review suggested a large reduction in TED
with fondaparinux37 but there is to date no evidence of a survival benefit with this
treatment5.
The possibility ofpublication bias in the papers published on the effect of heparin on
mortality following hip fracture may be of importance when comparing the findings of
the analysis presented in chapter 5 with the published literature. However it should be
noted that funnel plots such as the one shown in fig 2.2 are a relatively crude approach
in the detection ofpublication bias46.
2.7 Studies published after completing the literature review
One prospective cohort study published after completing the literature review provides
additional relevant information. Roche et al followed up hip fracture patients admitted
between 1999 and 2003 (n=2448, mean age 82) for a year in order to study the influence
of a number of cofactors and comorbidities on mortality. Previously diagnosed CVD
was not found to have a statistically significant effect on mortality in multivariate
analysis, but this finding was perhaps explained by the strong effect of cardiac failure
postoperatively (HR 5.0; 95% CI 3.9 to 6.5), an observation that has parallels with the
discussion around Nettleman et aTs study in section 2.6.2. A minority of patients
(10%) were recorded as being current smokers, but smoking status did not appear to
influence mortality in either univariate or multivariate analysis. This provides
information that was missing in the papers identified for the literature review. All
patients received LMWH as thromboprophylaxis. Clinically apparent TED was
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identified during the inpatient stay in 1.7% (95% CI 1.2 to 2.2) of patients, each of
whom underwent radiological testing to confirm the clinical diagnosis47.
2.8 Grey literature published after completing the literature review
The House of Commons Health Committee produced a report in 2005 about
4o
thromboprophylaxis in hospitalised patients . The report provides expert opinion about
use of thromboprophylaxis in different contexts.
Mr David Warwick summarised the evidence for and against different types of
thromboprophylaxis in orthopaedic surgery for the Health Committee, on behalf of the
Royal College of Surgeons. His advice contrasts with that of the most recent SIGN
# T
guidelines on hip fracture but concurs with the most recent American College of Chest
Physicians guidelines5 by recommending against use of aspirin and advising use of
LMWH as thromboprophylaxis. SIGN has specifically addressed the difference
between the advice in its own guidelines and that of the American guidelines in the
most recent SIGN guideline on thromboprophylaxis18. However, as identified earlier,
there are insufficient data in existing trials to prove or disprove a survival benefit with
aspirin, heparin or different types of mechanical thromboprophylaxis following hip
fracture19'20. Warwick also stated that, in the case of fondaparinux, "risk reductions
presented for DVT are enticing"48. However, as identified in section 2.5.3, existing
trials with fondaparinux are based on clinical and radiological evidence of TED rather
than survival.
A manufacturer of graduated elasticated compression stockings and other mechanical
devices also provided evidence to the Health Committee. They presented an argument
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for the use of mechanical thromboprophylaxis based on the theoretical influence on the
pathogenesis of TED using Virchow's triad, and trial evidence-based on clinical
endpoints rather than survival.
In summary, while the House of Commons Health Committee report does not add to the
evidence base for thromboprophylaxis following hip fracture, it reinforces that
thromboprophylaxis is, as stated at the beginning of Warwick's evidence, "a
controversial and changing topic"48.
2.9 Implications of the findings of the literature review for the
design of the study described in subsequent chapters
Estimates of the incidence of TED from the literature review can be used to estimate the
sample size required to detect a treatment effect of thromboprophylaxis on secondary
outcomes for use in chapter 5 (see section 1.9 for the equivalent calculation for all cause
mortality). The Cochrane review of thromboprophylaxis in hip fracture patients
identified a 40% relative risk reduction in DVT with heparin, but there were insufficient
data to provide the equivalent estimate for PE19. With an estimated incidence of TED of
3% during the year following hip fracture29'30, the estimated sample size to detect a 40%
96
reduction in TED with heparin is 2500 per study limb (alpha = 5%, power = 80%) .
However, based on earlier work, the incidence of TED following hip fracture identified
using SMR data is between 1 and 2%25, so the required sample size may be substantially
higher. The sample size for different types of thromboprophylaxis including aspirin and
GEC stockings is also likely to be higher as fewer patients are documented as receiving
these types of thromboprophylaxis than heparin in the SHFA database25.
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Chemical thromboprophylaxis, including heparin and aspirin, may also influence
cardiovascular outcomes following hip fracture. Including these outcomes in the
secondary endpoint would increase the statistical power of the study. In the studies
identified in the literature review, Gerber et al identified cardiovascular events in 8% of
90
patients in the year following hip fracture , Vajanto identified myocardial infarction
• • • 90 •
(MI) in 1.5% and cerebral infarct in 1.2% of patients respectively , while the results of
autopsy studies suggest that about one quarter of hip fracture deaths are attributable to
TED or MI in the first three months following hip fracture (table 2.6).
Ideally, all cardiovascular events would be included in the analysis described in
subsequent chapters. However, the consequences of using chemical
thromboprophylaxis on the two most common types of stroke (thrombotic and
haemorrhagic) are very different, and details about the type of stroke are often
• 9 S
incomplete in the SMR database . As a result the only type of CVD included in the
secondary endpoint is coronary heart disease (CHD) - combined deaths and inpatient
episodes due to MI or angina.
Fatal haemorrhage was rare both in clinical studies (0.1% at up to 3 months follow
up33,34) and autopsy studies (2.8% autopsies - table 2.6), regardless of whether the
studies were conducted prior to the widespread use of thromboprophylaxis or in later
studies where thromboprophylaxis was used in the majority of patients. Major
haemorrhage and use of transfusion were also recorded infrequently. These results are
consistent with the findings of the Cochrane review of thromboprophylaxis in hip
fracture, which observed no evidence of significant or clinically important excess blood
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loss or haemorrhagic events with heparin19. A preliminary investigation of Scottish
Morbidity Records data also identified that haemorrhagic events were rare in the hip
fracture patients studied in subsequent chapters*. Haemorrhagic events will not
therefore be included as a secondary outcome in the analysis presented in subsequent
chapters.
2.10 Conclusions
There is a lack of recent data about the long-term incidence of TED following hip
fracture in the modern era of hip fracture treatment, which will be studied further using
SMR data (chapter 3).
The literature review has identified a number of cofactors and comorbidities that have
an important influence on morbidity and mortality following hip fracture. The majority
of these factors are included in SMR (chapter 3) and/or SHFA data (chapter 4).
There remains limited information about the effectiveness of different types of
thromboprophylaxis over placebo in reducing mortality following hip fracture. The
*
Haemorrhage (gastrointestinal, intracerebral or general haemorrhage) was identified during the
index admission with hip fracture or in death records during the year following hip fracture
admission in 86/8470 patients (1.02%; 95% CI 0.80 to 1.23%).
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findings of the analysis presented using SHFA data (chapter 4) and linked SHFA-SMR




2.11 Figures and tables
Figure 2.1 Selection of studies in the literature review
Step 1:
Ovid search




























• 30 (33.3%) general hip fracture
• 19 (21.1%) subgroups
• 12(13.3%) data duplicated
• 11 (12.2%) other reference types
• 9 (10.0%) methodological flaws
• 6 (6.7%) all lower limb surgery
• 2 (2.2%) foreign language




118 references 20 excluded:
3 general hip fracture, 2
duplicate data, 13 foreign
language, 2 editorial
27 papers identified from
other references and Web
of Science citation search
35 for final selection:
•23 (65.7%) incidence TED
(including 4 autopsy studies)
•12 (34.3%) comorbidities
At stage 6, "other reference types" include letters, reviews and comment.
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Figure 2.2 Funnel plot of studies of the influence of heparin on mortality
in hip fracture patients identified in the Cochrane review of
thromboprophylaxis in hip fracture
The funnel plot shown uses data from the Cochrane review of
thromboprophylaxis in hip fracture19. The plot shows an estimate of the
treatment effect with heparin (log (relative risk)) along the x-axis against an
estimate of the precision of the estimate (standard error of log (relative risk))
along the y-axis. The vertical line shows the log of the pooled estimate of
relative risk. Overall, 42/356 of the group receiving heparin and 38/374 of the
control group died - equivalent to a relative risk of 1.16 (95% CI 0.77 to 1.74).
If there was no publication bias and there was little heterogeneity between
studies, then the plot would resemble a filled in funnel, with a wide spread of
points at the base of the plot (low precision estimates), and a narrow spread of
points at the top (high precision estimates). The test for heterogeneity using a
standard chi-squared test was not statistically significant (x2 =0.16, p=0.69).
The preponderance of points on the left side of the plot suggests that studies
showing a protective effect with heparin were published preferentially, and that
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Table2.2Studieswh repatientserecruit dprospectivelynimwastu yTEDrm dicalcomplica ions followinghipracture CT=omputerisedt mographyscan,$fe le,S#fra ture,sdtan arddevi tion. Authors, countryand yearof publication ofstudyNpat¬ ientsDVT N(%)PE N(%)TED N(%)Thrombo¬ prophylaxisStudydesignRadiology
Dur¬ ation of follow -up
Mean agein years (range)




Allpatients received LMWHon admission
Prospectivetudy usingdatafrom patientsadmittedto asinglehospital between1989and 1998,toidentifyhe incidenceofPE followingmajor orthopaedic surgery








45%of patients receivedun- fractionated heparinuntil mobilised




Examination1 year.Cardiovascular outcomesrecord din 32patients(8.1%)
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Allpatients received LMWHfrom admission
Prospectivetudy

















13 fatal PEs (2.2)
31 (5.3)
46%of patients received chemical thrombo¬ prophylaxis
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Dur¬ ation of follow -up
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94%of patients receivedTP (mechanical orchemical)
Retrospectivestudy usingdata collectedbetw en 1995and9to identifythe incidenceofTED followinghip fracture
Ultrasound
or ventilation perfusion scan
3
mnths
83$ (range 50- 104), 78c? (range 16-98)
Includessomey ung r patients.61atients excludedduto missinginformation.




47%of patients received dextran
Retrospectivestudy usingdata collectedbetween 1976and85to identify complications followinghip fracture
Veno¬ graphyor ventilation- perfusion scan
Hip# adm¬ ission
76 (range 22-92)
607fractures.In l des somey ung rpatients andbout1/3were men.
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Dur¬ ation of follow -up
Mean agein years
Notes-including potentials urcesf bias




Retrospectivestudy usingdata collectedbetw en 1982and93to identifymedical complications followinghip fracture
Ultra¬ sound, venogram, ventilation- perfusion scanor pulmonary angiogram
Hip# adm¬ ission
80.2
Providesdetail d information(including diagnosticinformation) aboutmedicalproblems identifiedur ngthh p fractureadmission.















Allpatients givenLMWH pre-and post-op




334fractures.In l des somey ung rpatients.
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Doubleblind RCT(LMWH versus placebo) conducted between2001 and2002
Extensive radiological invest¬ igations partof RCT
32days
79 (range 23-96)






Prospective studyof functional status conducted between1986 and1997
Veno¬ graphyor ventilation- perfusion scan
Hip# adm¬ ission
Range 65-79
Only10%male, exclusionsincluded dementiaandpoor mobility.
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Table 2.5 Autopsy studies providing data about the proportion of deaths
attributable to PE following hip fracture











Prospective study of 806
hip fracture patients
admitted to hospital





















autopsy reports of 581
hip fracture patients who
















3 fatal PE, 5 contributed to death. Median time to death 31 days.
#
The majority of fatal PE occurred in the first 30 days.
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Bronchopneumonia 290 42.8 (39.1 to 46.6)
Congestive cardiac failure 97 14.3 (11.7 to 17.0)
Not known/ other 40 5.9(4.1 to 7.7)
Sepsis 27 4.0 (2.5 to 5.5)
Stroke (other)* 3 0.4 (0 to 0.9)
Multiple 15 2.2 (1.1 to 3.3)
Renal failure 9 1.3 (0.5 to 2.2)
Cancer 2 0.3 (0 to 0.7)




Pulmonary embolism 89 13.1 (10.6 to 15.7)
Myocardial infarction 71 10.5 (8.2 to 12.8)
Stroke (thrombotic) 11 1.6 (0.7 to 2.6)
Other arterial thrombosis 3 0.4 (0 to 0.9)




bleed 13 1.9 (0.9 to 3.0)
Aneurysm 4 0.6 (0 to 1.2)
Stroke (haemorrhagic) 2 0.3 (0 to 0.7)
Total haemorrhage 19 2.8(0 to 4.1)
Total 677 100.0%
"




Table 2.7 Common medical problems documented prior to hip fracture
admission
There was considerable heterogeneity between papers so the figures shown
are the median proportion of the different papers and the range.




Ischaemic heart disease 36.4 17.7 to 50.3 32;33;39;59
Congestive cardiac failure 11.7 7.6 to 15.8 32;59;63;64
Stroke 9.7 8.1 to 19.2 32; 59
Myocardial infarction in





Diabetes 10.4 5.9 to 43.9 33;39;51;59;61;
63;64
Dementia 10.0 4.5 to 39.6 30;32;33;51;64
Respiratory disease 10.0 4.3 to 14.9 32;39;51;59-64
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3 Scottish Morbidity Records (SMR)
3.1 Introduction
The literature review (chapter 2) has demonstrated the association between various
patient factors, social factors and medical comorbidities on outcome following hip
fracture. Routinely collected hospital discharge records provide one potential method of
identifying medical comorbidities in hip fracture patients. Changes in the quality of
these data over time are explored. The identification of variables that have been
collected consistently over time provides the opportunity to test whether hip fracture
outcomes have changed with the introduction of modern treatment. Subsequent
chapters focus on the analysis of a subgroup of SHFA participants with complete SHFA
and SMR data admitted with hip fracture between 1998 and 2003 (see section 4.4.1).
Data from the complete SMR extract collected during the same period is used to
compare the characteristics of this subgroup of SHFA participants, to assess the
representativeness of these patients.
3.2 Background
SMR records are routinely completed for each inpatient episode under the care of a
consultant in NHS hospitals in Scotland. SMR records can be linked together for
individual patients, allowing the study of continuous inpatient stays under the care of
successive hospital consultants. Additionally, SMR data are now linked to the cancer
register and mortality records. Using the postcode of the patient, it is also possible to
link to area-based measures of socio-economic status.
SMR data are collected for administrative purposes. In the 1990s there was an increase
in the accuracy of the data collected. Reasons for this increase in accuracy included the
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introduction of a Data Quality Assurance team at the Information Services Division
(ISD) of National Services Scotland in 199065, and the introduction of the Internal
Market in 1991. The Internal Market depended on high quality information to allow the
calculation of costs for reimbursement and commissioning purposes. The Internal
Market was, however, short lived, ending with legislation passed in 199866. While
earlier work has shown the increased detail available from SMR records for hip fracture
patients during the period of the Internal Market , it is not clear whether this trend has
reversed since the dissolution of the Internal Market. SMR data also provide data about
outcome, by linking to subsequent inpatient episodes and death records. Using SMR
data, therefore, it is possible to study the influence of comorbidities on long-term
outcomes. Combining these findings with those presented for SHFA participants in
chapter 4 allows comprehensive adjustment for multiple cofactors and comorbidities, as
detailed in chapter 5.
The first national evidence-based hip fracture guideline in Scotland was published by
• 17 •• •••• . .
SIGN in 1997 . The publication of this guideline in July 1997 and its dissemination at
a national hip fracture conference in August 1997 pinpoints the time at which
thromboprophylaxis and other aspects of modern hip fracture care were first
documented on a national basis in Scotland. The recommendations of these new
guidelines were audited using a new expanded SHFA form from the start of 1998.
Nonetheless, SHFA reports published since 1998 have shown variable uptake of the
advice given in successive hip fracture guidelines in hospitals across Scotland67. The
impact of this move to an audited evidence-based approach for hip fracture care on
outcomes for patients has not been studied previously.
60
3 Scottish Morbidity Records (SMR)
3.3 Rationale
3.3.1 Objective 2a. To assess the quality and reliability of SMR data
collected for hip fracture patients between 1986 and 2003
The quality and reliability of SMR data collected for patients admitted with hip fracture
between 1986 and 2003, is explored in order to identify the variables most suitable for
inclusion in the analysis of the linked SHFA-SMR database in chapter 5.
3.3.2 Objective 2b. To assess how survival following hip fracture has
changed since the publication of the first hip fracture guideline,
using SMR data collected between 1986 and 2003
The evidence-based approach to hip fracture care documented in hip fracture
guidelines17'18 should have resulted in an improvement in outcomes. However, over the
past twenty years, the age and comorbidities of patients at the time of hip fracture have
increased. Using the results presented for objective 2a, survival following hip fracture
is modelled, adjusting for age, sex and other comorbidities and cofactors.
3.3.3 Objective 2c. To assess the representativeness of a subgroup of
SHFA participants using SMR data collected between 1998 and 2003
In this chapter, SMR data for all hip fracture patients admitted between 1998 and 2003
(n=34012) are used to assess the representativeness of a subgroup of SHFA participants
(n=8470), comparing demographics, comorbidities and outcomes. Since this subgroup
of patients is studied in further detail in subsequent chapters, this analysis tests how well
the findings of subsequent chapters can be generalised to the elderly hip fracture
population in Scotland.
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3.4 Methods
3.4.1 Participants
Figure 3.1 shows the number of patients included in the various analyses presented in
this thesis. Cases were identified as "the first discharge for a patient aged 60 years and
over with a principal diagnosis of Fractured Neck of Femur for 1986-2003 in a non-
obstetric, non-psychiatric Scottish Hospital", using the following codes for hip fracture
(International Classification of Diseases (ICD)-9 code 820 or ICD-10 code S72.0-
S72.2). Private hospitals do not return SMR records and patients treated for hip fracture
in these institutions are therefore not included in this analysis. Data were available for
93520 patients aged 60 years and over admitted with a primary diagnosis of hip fracture
between 1986 and 2003 inclusive.
There were 34012 patients aged 60 and over recorded with hip fracture in the SMR
database between 1998 and 2003 inclusive. More detailed analysis of SMR data was
performed for a subgroup of SHFA participants (n=8470) admitted between 1998 and
2003 (section 4.4.1), representing 25% of hip fracture patients admitted between 1998
and 2003.
3.4.2 Ethical and privacy considerations
Analysis was performed according to current ethical and legal guidelines. SMR data
were anonymised following record linkage and prior to analysis. The study protocol
was discussed with the Caldicott Guardian of National Services Scotland. The record
linkage between SMR and SHFA databases was approved by the Privacy Advisory
Committee of National Services Scotland.
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3.4.3 Data collection
SMR data are collected routinely at the time of hospital discharge. Coding staff based
in hospitals use medical notes and consultant discharge letters to identify up to six
diagnostic codes per hospital discharge. Each consultant episode results in an SMR
discharge record. For example, a patient admitted to a general medical ward,
transferred to orthopaedics and discharged via a rehabilitation ward will have three
separate discharge records completed for that particular continuous inpatient stay. The
data recorded in the SMR database include the name, address, age and sex of the
patient, dates of admission and discharge, hospital, ward and speciality, a primary
diagnosis and up to five secondary diagnoses, and postcode. Data are then collected
centrally and quality assurance checks are carried out by the Data Quality Assurance
team at ISD which checks 1% of SMR returns. Most recently the accuracy rate for the
main diagnosis was 88%, but this has varied during the period 1990 to 200365.
3.4.4 Record linkage
Analysts at ISD have developed considerable experience in linking SMR records, as has
been described elsewhere68. The process of record linkage aims to bring together all
records for the same person, using probability matching to correct for factors that may
hinder the process including name changes, moving house and human error in entering
patient details. Automated algorithms have been developed that first produce a code
(New York State Intelligence Information System) and then compress the name
(Soundex) to circumvent problems with spelling. Records with similar blocks of
information such as Soundex code, postcode and age are brought together and then
matched in pairs within these blocks using probability matching. Thus, to continue the
example from section 3.4.3, the three separate records would, following record linkage,
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be considered together as a continuous inpatient stay. The record linkage for this study
used the approach laid out in figure 3.2.
The SMR records for each hip fracture patient were linked to SMR records for the five
years prior to the hip fracture admission and one year subsequent to the hip fracture
admission. Up until 1981, SMR used ICD-8, which does not map adequately to
subsequent coding systems (ICD-9 and ICD-10). As a result, the earliest date of study
was chosen as the start of 1986, allowing the study of previous inpatient episodes for
five years using ICD-9. The latest date of study (end of 2003) was chosen because the
end of 2004 was the last date for which complete SMR data were available from all
NHS Trusts in Scotland, providing outcomes up to one year following the date of the
hip fracture admission for each patient.
3.4.5 Data coding and extraction
Extraction and coding was performed following record linkage during July and August
2005. SMR records linked to the hip fracture admission were searched using a
computer programme written by analysts at ISD. Primary and secondary diagnostic
positions were searched using ICD codes listed in table 3.1*. Cancer register data were
*
ICD-9 codes were used between 1982 and end of March 1996 in SMR and between 1982 and
end of December 1999 in GRO death records. Thereafer ICD-10 codes were used.
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also searched for common types of cancer (excluding skin cancers other than
melanoma) and cancers that are known to metastasise to the bone (table 3.2).
Diagnoses recorded during inpatient episodes in the five years prior to hip fracture were
searched to identify factors that may influence outcome following hip fracture, as
identified for the literature review (objective lb). Examples of conditions that have
previously been shown to be associated with an adverse outcome include a prior
diagnosis of heart disease, respiratory disease, cancer and dementia. Secondary
diagnoses recorded during the index admission with hip fracture were also searched to
document pre-existing or concurrent medical conditions.
The SMR database also provides some information about social factors, in the form of
the Scottish Index of Multiple Deprivation (SIMD) which is assigned to individuals
based on their postcode69. This provides information on area-based measures of
deprivation using 31 indicators from six domains: current income, employment,
housing, health, education, skills and training and geographic access to services and
telecommunications. The information is based on data from a range of administrative
data collected by a number of central government departments, local government and
agencies including ISD. Data are available for 6505 "data zones" ranked in order of
deprivation, and are expressed in deciles of SIMD score in the SMR database.
Outcomes in the year following hip fracture admission were identified in two ways.
All-cause mortality (the primary endpoint) was identified from General Register Office
Scotland (GROS) records that are routinely linked to SMR. The secondary endpoint
was identified by searching GROS and SMR records for deaths and/or inpatient
episodes with CHD or TED.
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3.4.6 Statistical analysis
Statistical analysis was performed in Statistical Package for the Social Sciences (SPSS
version 11.5). Continuous variables were grouped as follows: for age, patients aged 60
to 69 years, 5-year groupings for patients aged 70 to 89 years, and 90 years and over;
for number of inpatient episodes in the five years prior to hip fracture, in groupings of 0
episodes, 1 episode, 2-3 episodes, 4-7 episodes and 8+ episodes.
The independent samples T test was used to compare means for continuous variables in
two groups. Analysis of variance was used to compare means for continuous variables
in more than two groups. The chi squared (% ) test was used to compare proportions
between two or more groups, testing for trend where appropriate. Where distributions
were highly skewed (for example the number of inpatient episodes and bed days spent
in hospital over the five years prior to hip fracture admission), further statistical analysis
was not attempted. Comparisons of patients included in SHFA and SMR data between
1998 and 2003 did not include testing for statistical significance because the majority of
patients recorded in SHFA were also recorded in SMR, so these were not independent
samples.
Cox proportional hazards regression analysis was performed using the forward
conditional method, checking for the assumption of proportional hazards using the log
minus log plot, and testing for interaction between age category, sex, and number/ type
of prior inpatient episodes for medical reasons. The outcome used in the Cox proportion
hazards regression analysis described in this chapter was all-cause mortality at up to 365
days following the date of hip fracture admission identified from General Register
Office Scotland (GROS) records linked to SMR.
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3.5 Results
3.5.1 Objective 2a. To assess the quality of SMR data collected for hip
fracture patients between 1986 and 2003 (n=93520)
3.5.1.1 Characteristics of hip fracture patients admitted between 1986 and
2003
\
Between 1986 and 1998 the number of hip fractures increased from 4380 to 5644 hip
fractures per annum, a 29% increase. Since 1999, however, the number of hip fractures
in Scotland per year has not increased, with a mean of 5674 fractures (range 5562 to
5816) per annum between 1999 and 2003.
The mean age of patients at hip fracture increased slightly from a mean of 79.9 years
(95% confidence interval (CI) 79.8 to 80.0) between 1986 and 1991, 80.5 years (95% CI
80.4 to 80.6) between 1992 and 1997, and 80.9 years (95% CI 80.4 to 80.5) between
1998 to 2003 (p<0.001). Men were on average 3.3 years (95% CI 3.2 to 3.4 years)
younger than women at the time of hip fracture (p<0.001). The proportion of males
increased slightly from 18.6% between 1986 and 1991, to 20.2% between 1992 and
1997 and 21.8% between 1998 and 2003 (pO.OOl).
3.5.1.2 Outcomes following hip fracture
Between 1986 and 2003 there were 28112 deaths (representing 30% of all hip fracture
patients) recorded in the year following hip fracture admission. The crude mortality rate
at a year following hip fracture increased slightly over time, from 29.6% (95% CI 29.1
to 30.1%) between 1986 and 1991, 29.8% (95% CI 29.3 to 30.3%) between 1992 and
1997, and 30.7% (95% CI 30.2 to 31.1%) between 1998 and 2003 (p=0.003). Mortality
one year after hip fracture admission was higher in men than women at 39.2% (95% CI
67
3 Scottish Morbidity Records (SMR)
38.5 to 39.9%) and 27.7% (95% CI 27.4 to 28.1%) respectively (p<0.001). Mortality
did not change significantly over time for men, but increased for women from 27.3%
(95% CI 26.8 to 27.9%) between 1986 and 1991, to 27.5% (95% CI 26.9 to 28.0%)
between 1992 and 1997, and 28.3% (95% CI 27.8 to 28.9%) between 1998 and 2003
(p=0.01).
/
3.5.1.3 Inpatient episodes in the five years prior to hip fracture
The median number of inpatient episodes in the five years prior to hip fracture increased
between 1986 and 2003 from 1 to 2 episodes. The median number of days spent in
hospital over the five years prior to hip fracture also increased, from 6 days for patients
admitted with hip fracture between 1986 and 1991 to 8 days for patients admitted with
hip fracture between 1998 and 2003.
3.5.1.4 Types of previous and current medical problems recorded for hip
fracture patients.
Tables 3.3a and 3.3b show the proportion of hip fracture patients with a primary or
secondary diagnosis of different groupings of medical diagnoses during the five years
prior to hip fracture. Figure 3.3 shows the proportion of patients with a primary or
secondary diagnosis of these medical conditions in the five years prior to hip fracture -
the proportion of patients with these conditions increased by 91% from 34.9 to 66.7%
(pO.OOl).
Cancer data presented in tables 3.3a and 3.3b show that there was a 221% increase in
coding for prior inpatient episodes where cancer was documented using SMR data
between 1986 and 2003. However, using cancer registration data included in the SMR
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database, the proportion of patients with previous episodes with any of the cancer types
listed in table 3.2 increased by only 14% from 4.1% for the period 1986 to 1991 to 4.7%
for the period 1998 to 2003 (%2 for linear trend = 10.5, p<0.001).
3.5.2 Objective 2b. To assess how survival following hip fracture has
changed since the publication of the first hip fracture guideline,
using SMR data collected between 1986 and 2003 (n=93520)
As described above, the crude mortality rate up to a year following hip fracture
increased slightly between 1986 and 2003. However, other characteristics of hip
fracture patients changed over the same period, including distribution of age, sex and
the number of co-existing medical conditions. Cox proportional hazards regression was
used to adjust for age, sex and previous inpatient episodes. Results of univariate and
multivariate analysis are shown in tables 3.4 and 3.5 and figure 3.4.
Compared to hip fracture patients admitted between 1986 and 1991, unadjusted
mortality at a year following hip fracture did not change for hip fracture patients
admitted between 1992 and 1998, but increased for hip fracture patients admitted
between 1998 and 2003 (hazard ratio 1.04; 95% CI 1.01 to 1.07; p=0.01). However
after adjusting for age, sex, number of previous inpatient episodes, inpatient episodes
with CVD or respiratory disease, or prior registration with cancer, mortality appeared to
reduce over time, with a hazard ratio 0.91 (95% CI 0.89-0.94; p<0.001) for hip fracture
patients admitted between 1992 and 1997 and a hazard ratio of 0.87 (95% CI 0.85 to
0.90; p<0.001) for hip fracture patients admitted between 1998 and 2003. The log
minus log curves ran closely parallel to each other suggesting that the assumption of
proportional hazards with this model was valid. The model showed that age, male sex,
and previous cancer registration were the strongest predictors of mortality. There were
69
3 Scottish Morbidity Records (SMR)
significant interactions between age and sex, number of previous inpatient episodes and
previous diagnoses, but these did not influence the hazard ratios presented above. The
analysis was repeated, replacing previous inpatient episodes with CVD with inpatient
episodes with a primary diagnosis of acute MI but this did not influence the hazard
ratios presented above. Similarly, including previous inpatient episodes with dementia
andJ or diabetes as an additional covariate did not influence the findings.
3.5.3 Objective 2c. To assess the representativeness of a subgroup of
SHFA participants using SMR data collected between 1998 and 2003
(n=8470)
A subgroup of SHFA participants admitted between 1998 and 2003 (n=8470) had
complete SMR and SHFA data and are compared here with the hip patients identified
from the complete SMR extract during the same period.
The subgroup of SHFA participants were older (81.6 years; 95% CI 81.4 to 81.8 years)
than hip fracture patients in the complete SMR extract (80.9 years; 95% CI 80.8 to 81.0
years). A higher proportion of the subgroup of SHFA participants were women (80.7%;
95% CI 79.8 to 81.6%) compared with the complete SMR extract (78.2%; 95% CI 77.7
to 78.6%). The geographic distribution of cases was different between the groups with
under-representation from more deprived areas such as Greater Glasgow for the
subgroup of SHFA participants (figure 3.5). SIMD data recorded in SMR provide
further evidence that patients from more deprived areas were under-represented in the
subgroup of SHFA participants. For the complete SMR extract, 33533 (98.6%) hip
fracture patients had SIMD data available and of these patients 15636 (46.6%) were
from SIMD deciles 1-5 (more affluent). All the subgroup of SHFA participants had
SIMD data and 4525 (53.4%) were from SIMD deciles 1-5.
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Table 3.6 shows a comparison of the number of inpatient episodes with medical
conditions in the five years prior to hip fracture for hip fracture patients from the
complete SMR extract and the subgroup of SHFA participants. A higher proportion of
the SHFA participants had previous inpatient episodes documented than hip fracture
patients from the complete SMR extract. Table 3.7 shows that previous inpatient
episodes with cardiovascular disease were more common in the subgroup of SHFA
participants, but that they were slightly less likely to have had previous inpatient
episodes with respiratory disease or cancer registration.
The mortality rate at a year was lower for the subgroup of SHFA participants (29.9%;
95% CI 28.9 to 30.9%) than for hip fracture patients from the complete SMR extract
(30.7%; 95% CI 30.2 to 31.1%). The primary causes of death for the 2531 SHFA
participants who died in the year following hip fracture admission are listed in table 3.8
The most commonly recorded causes of death following hip fracture were diseases of
the heart and circulation (37%) and trauma (18%). Inpatient episodes and deaths
recorded for the secondary endpoint are summarised in table 3.9 (3.9a shows hospital
inpatient episodes and 3.9b shows deaths). Overall, 7.4% (95% CI 6.9 to 7.8%) of hip
fracture patients from the subgroup of SHFA participants had the secondary endpoint
recorded during the year following hip fracture, compared to 7.5% (95% CI 7.2 to
7.8%) of hip fracture patients from the complete SMR extract.
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3.6 Discussion
3.6.1 Quality of data
Understanding the potential influences on quality of SMR data is central to the analysis
• • • 9 S
presented in subsequent sections and chapters. Consistent with earlier work , the
proportion of patients with medical comorbidities recorded during inpatient episodes in
the five years prior to hip fracture increased during the 1990s (figure 3.3). There were
large increases in the documentation of a number of medical conditions including
dementia and diabetes, particularly in the secondary diagnostic positions (table 3.3b).
While there would have been expected to be some increase in the proportion of patients
with these conditions over time as the age of patients at the time of hip fracture
increased, a substantial part of the increase is likely to be explained by the changes in
recording of routinely collected hospital discharge data. Possible reasons include the
introduction of the Internal Market, increased use of computer technology in hospital
record management, and changes in medical management. These questions about the
quality of data for some medical conditions may explain why inclusion of diabetes
mellitus and dementia did not influence the multivariate analysis of trends in hip
fracture survival (section 3.5.2).
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There were more modest increases in other conditions including inpatient episodes with
CVD* or a primary diagnosis of respiratory disease. Cardiovascular conditions such as
acute MI, unstable angina or stroke, and respiratory conditions such as pneumonia and
acute exacerbation of chronic obstructive pulmonary disease frequently lead to
hospitalisation and may therefore have been more accurately recorded than other
conditions principally managed in primary care. However, it is difficult to assess the
accuracy of these data. Secular trends in CVD suggest that while mortality due to CVD
decreased rapidly in men and fell slightly in women during the last two decades70, the
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consequences of ischaemic heart disease, including heart failure, are increasing .
However, data describing trends in morbidity and inpatient episodes related to CHD in
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many parts of the UK are limited, particularly for the elderly and for women , the
groups at highest risk of hip fracture. The relatively large increase in respiratory disease
may reflect high smoking rates in Scottish women in the latter half of the twentieth
century73. Cancer registry data collected during the period of this study has been
collected using an extended and quality assured data collection system, based on
Based on the findings of tables 3.3a and 3.3b this was defined as primary or secondary
diagnosis of acute Ml or stroke or primary diagnosis of IHD, other heart disease or peripheral
vascular disease. There was a 32% increase in the proportion of patients with previous
admissions with documentation of CVD, from 17.2% between 1986 and 1991 to 22.7% between
1998 and 2003). This definition did not include surgical codes for coronary artery bypass
grafting, and did not include patients admitted as day cases for coronary angioplasty.
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notifications from multiple sources, so the accuracy of cancer diagnoses is likely to have
been high74.
The primary endpoint, all-cause mortality, is likely to have been recorded accurately, as
death certification is required by law. The secondary endpoint was studied in order to
explore the influence of thromboprophylaxis on CHD and TED. However these
outcomes are likely to have been less accurately identified or recorded than all-cause
mortality. The quality of recording for primary and secondary endpoints is considered
further in chapter 5.
3.6.2 Trends in mortality following hip fracture
The data presented in tables 3.4 and 3.5 illustrate the importance of adjusting for
cofactors and comorbidities. In univariate analysis, mortality following hip fracture
appeared to increase over time. However, after adjusting for age, sex and comorbidities
in multivariate analysis, mortality following hip fracture appeared to fall over time.
While the cofactors and comorbidities included in the analysis have been shown in the
literature review to be important in predicting hip fracture outcomes, there remains the
possibility of residual confounding.
The apparent fall in adjusted mortality over time may be explained by evidence-based
changes to medical, anaesthetic and/ or surgical management. However mortality
following hip fracture remains high and the challenge now is to maximise the use of
interventions that have the greatest impact on mortality. Unfortunately many
randomised controlled trials study surrogate endpoints and are underpowered to detect
an influence on mortality. In the case of TED following hip fracture, for example, firm
recommendations cannot be made about thromboprophylaxis regimes based on existing
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evidence as discussed in the literature review. Therefore, despite publication of national
hip fracture guidelines and evidence of a reduction in mortality in this study, further
adequately powered studies of survival following hip fracture survival are required.
Cox proportional hazards regression analysis, used in the study of trends in mortality in
this chapter, also forms the basis of statistical analysis in subsequent chapters. Cox
proportional hazards regression analysis uses the time from hip fracture admission to
death, providing an instantaneous estimate of the hazard ratio at all time points. The
technique depends on the assumption that the reduction in hazard is the same at all time
points, whether during the period immediately following surgery when mortality rates
were likely to have been high, or during the period of recuperation when mortality rates
were likely to have started to decrease. This assumption was tested by examining the
log minus log plot, which, in this analysis, showed that the assumption of proportional
hazards was valid. A number of models were fitted to the data, testing for interactions
between variables. There were therefore a number of benefits to using Cox proportional
hazards regression analysis: it used all the available information including time to
outcome, allowed sophisticated adjustment for a number of cofactors and comorbidities,
and was quick to perform in SPSS. Alternative approaches such as logistic regression
would not have used some of the information available (time to event), while the
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analysis required to perform a cohort study would be time consuming and would have
had less statistical power as patients would need to be matched for other comorbidities
and cofactors*.
3.6.3 Representativeness of patients included in the analysis
The SMR data described above do not include information about patients who were
treated conservatively at home or community hospitals, patients who died before
admission to a hospital ward (including patients who died in Accident and Emergency),
or patients admitted to private hospitals. However there are likely to have been very
small numbers in each of these categories so the findings are likely to be applicable to
the majority of elderly hip fracture patients. Patients under 60 years old were excluded
from analysis because the reasons for fracture and the subsequent outcomes in younger
patients differ substantially from elderly patients with hip fracture.
There were some differences between the total population of hip fracture patients
described using SMR data and the subgroup of SHFA participants studied in subsequent
*
A cohort study was conducted, matching patients for age category, sex, previous admissions
with cardiovascular disease or respiratory disease, cancer registration, and number of hospital
admissions in the previous five years. The comparison was for patients admitted between 1986
and 1997 and patients admitted between 1998 and 2003. Matching was achieved for 64408
(66.7%) of the 93520 patients aged 60 years and over. The relative risk comparing mortality
between 1998 and 2003 with mortality between 1986 and 1997 was estimated at 0.93 (95% CI
0.91 to 0.95), and is therefore consistent with the findings of multivariate analysis (table 3.5).
76
o bconisn MorDiaity Kecoras (bMKj
chapters. Compared to all hip fracture patients recorded in SMR and admitted between
1998 and 2003, the subgroup of SHFA participants were older, were more likely to be
women, had a lower mortality rate at a year and were less likely to have lived in
deprived areas. The difference in mortality rates may reflect differences in the
proportions of men between the groups, as men were much more likely to die than
women in the year following hip fracture. The subgroup of SHFA participants were
also more likely to have been admitted to hospital in the past and this may reflect age
and sex differences between the two groups, but it is also possible that these differences
are explained by the inverse care law, where patients from deprived areas are less able
to access medical services75. Overall, however, the differences between the subgroup of
SHFA participants and other hip fracture patients were relatively small and the
subgroup of SHFA participants is likely to have been reasonably representative of the
general population of elderly hip fracture patients.
3.7 Conclusions
The analysis presented in this chapter was performed primarily to assess the
completeness and accuracy of SMR data for use in subsequent chapters. There are a
number of limitations to using hospital discharge data, relating to accuracy, changes in
quality over time, and completeness. Nonetheless, these data provide potentially useful
information about comorbidities and outcomes in hip fracture patients that will be
explored in subsequent chapters. The findings of this chapter suggest that results for the
subgroup of SHFA participants can be generalised to the general elderly hip fracture
population. The analysis presented in this chapter has also provided data on trends in
mortality, adjusted for cofactors and comorbidities.
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Figure 3.2 Approach used for record linkage
After identifying the index admission with hip fracture, inpatient episodes in the
five years prior to hip fracture, and inpatient episodes and deaths in the year
following hip fracture were identified.
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Figure 3.3 Proportion of hip fracture patients aged 60 and over with
inpatient episodes documented for medical reasons in the five years prior
to hip fracture
n=93520
Source: Scottish Morbidity Records (1986 to 2003)
Year
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Figure 3.4 Cox proportion hazards survival functions (plotted at mean of
covariates) for patients admitted with hip fracture during three different
time periods, adjusted for cofactors shown in table 3.5
n=93520
Source: Scottish Morbidity Records (1986 to 2003)
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Figure 3.5 Geographical distribution of patients aged 60 years and over
admitted to NHS hospitals in Scotland with hip fracture between 1998 and
2003, by health board of residence, in SMR and SHFA databases
Results are shown for all patients admitted with hip fracture (labelled "SMR",
n=34012) and a subgroup of patients with complete SMR and SHFA data
(labelled "SHFA", n=8470).
The graph shows the proportion of the total number of patients in each group
who were resident in each of the mainland health boards. For example, while
18% of all hip fracture patients were resident in Glasgow in the complete SMR
extract, only 1% of hip fractures patients included in the subgroup of SHFA
participants were resident in Glasgow. Patients from Glasgow were therefore
underrepresented in the analysis of SHFA data.
This graph does not show the results for the island health boards. Data were
complete for the subgroup of SHFA participants, but data were not available for
479 (1.4%) patients in the complete SMR database.
A&C = Argyll and Clyde, A&A = Ayrshire and Arran, D&G = Dumfries and
Galloway, FV = Forth Valley, GG = Greater Glasgow.













□ SHFA 21% 2% 6% 0% 7% 5% 1% 12% 12% 9% 14% 11%
■ SMR 9% 7% 2% 3% 7% 5% 18% 10% 4% 9% 15% 8%
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Table 3.1 List of diagnoses identified in SMR analysis
Diagnosis ICD-9 codes ICD-10 codes
Acute myocardial infarction (Ml) 410 121-122
Ischaemic heart disease (IHD) other
than Ml
411-414 120, 123-125
Pulmonary embolism 415 126
Heart disease (other than IHD or PE) 393-398, 416-429 105-109, 127-152
Hypertension 401-405 110-115
Deep vein thrombosis 451.0-451.2 I80.0-I80.3
Diseases of the circulatory system







Diseases of the respiratory system
including pneumonia and chronic
obstructive pulmonary disease
460-519 J00-J99
Cancer (excluding non melanoma skin
cancer)
140-172, 174-208 C00-C43, C45-C97








3 Scottish Morbidity Records (SMR)
Table 3.2 List of cancer diagnoses used for cancer registration search
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Table 3.3 Medical diagnoses recorded on hospital discharge records in
the five years prior to hip fracture admission
Primary (table 3.3a) and secondary (table 3.3b) diagnoses on discharge records
in the five years prior to hip fracture admission for patients aged 60 years and
over admitted to NHS hospitals in Scotland with hip fracture (n=93520).
Primary and secondary diagnoses are mutually exclusive, so, for example, a
patient with a primary diagnosis of respiratory disease was not counted again if
they also had coding for an admission with a secondary diagnosis of respiratory
disease.
n=93520
Source: Scottish Morbidity Records (1986 to 2003)
Table 3.3a
Primary diagnoses in the five years prior to hip fracture








Respiratory disease 1939 (6.9) 2658 (8.5) 3510 (10.3) 50
Stroke 1917 (6.8) 2295 (7.3) 2551 (7.5) 10
Other heart disease 1122 (4.0) 1793 (5.7) 2349 (6.9) 74
Cancer 475 (1.7) 696 (2.2) 1769 (5.2) 209
PVD 892 (3.2) 1181 (3.8) 1354 (4.0) 26
IHD (other than Ml) 507 (1.8) 882 (2.8) 1292 (3.8) 111
Ml 621 (2.2) 779 (2.5) 845 (2.5) 13
Dementia 586 (2.1) 793 (2.5) 811 (2.4) 15
Diabetes mellitus 356(1.3) 303 (1.0) 346 (1.0) -20
DVT 78 (0.3) 178 (0.6) 299 (0.9) 218
Hypertension 128 (0.5) 142 (0.5) 173 (0.5) 12
PE 43 (0.2) 81 (0.3) 127 (0.4) 145
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Table 3.3b
Secondary diagnoses in the five years prior to hip fracture admission or during
the index admission for hip fracture.
n=93520








Respiratory disease 1494 (5.3) 2357 (7.5) 4275 (12.6) 137
Other heart disease 1367 (4.9) 2258 (7.2) 4146 (12.2) 151
Dementia 1051 (3.7) 2334 (7.5) 4119 (12.1) 225
IHD (other than Ml) 748 (2.7) 1756 (5.6) 3667 (10.8) 306
Hypertension 369 (1.3) 1000 (3.2) 3047 (9.0) 584
PVD 560 (2.0) 1167 (3.7) 2456 (7.2) 263
Diabetes mellitus 570 (2.0) 957 (3.1) 1814 (5.3) 164
Stroke 323 (1.1) 405 (1.3) 591 (1.7) 52
Cancer 108 (0.4) 212 (0.7) 490 (1.4) 276
Ml 359 (1.3) 343 (1.1) 475 (1.4) 10
DVT 79 (0.3) 186 (0.6) 242 (0.7) 154
PE 159 (0.6) 177 (0.6) 203 (0.6) 6
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Table 3.4 Results of Cox proportion hazards regression analysis for
patients admitted with hip fracture during three different time periods
between 1986 and 2003 (univariate analysis).
n=93520






Age (years)' 60-64 4141 (4) 1.0
65-69 6735 (7) 1.3 (1.2 to 1.4) <0.001
70-74 10989 (12) 1.7 (1.6 to 1.9) <0.001
75-79 17332 (19) 2.2 (2 to 2.4) <0.001
80-84 21953 (23) 2.7 (2.5 to 3) <0.001
85-89 19826 (21) 3.4 (3.1 to 3.7) <0.001
90+ 12544 (13) 4.6 (4.2 to 5.1) <0.001
Sex Men 18982 (20) 1.0





0 episodes 31678 (34) 1.0
1 episodes 17563 (19) 1.4 (1.3 to 1.4) <0.001
2-3 episodes 22064 (24) 1.6 (1.6 to 1.7) <0.001
4-7 episodes 15905 (17) 2 (1.9 to 2) <0.001




No 85413 (91) 1.0
Yes 8107 (9) 1.9 (1.8 to 1.9) <0.001
Admission with
CVD
No 74652 (80) 1.0
Yes 18868 (20) 1.7 (1.7 to 1.8) <0.001
Cancer
registration
No 89352 (96) 1.0
Yes 4168(4) 2.2 (2.1 to 2.2) <0.001
Period of hip
fracture
1986 to 1991 28180 (30) 1.0
1992 to 1997 31328 (33) 1 (0.98 to 1.03) 0.8
1998 to 2003 34012 (36) 1.04 (1.01 to 1.07) 0.01
Due to the large size of the dataset available for the analysis presented in tables 3.4 and 3.5 it
was possible to divide 60 to 69 year olds into two groups. Elsewhere in this thesis patients
aged 60 to 69 years old have been analysed as a single group (see section 3.4.6).
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Table 3.5 Results of Cox proportion hazards regression analysis for
patients admitted with hip fracture during three different time periods
between 1986 and 2003 (multivariate analysis).
n=93520
Source: Scottish Morbidity Records (1986 to 2003)
Variable Category Hazard ratio
(95% CI)
p value
Age (years) 60-64 1.0
65-69 1.3 (1.2 to 1.4) <0.001
70-74 1.8 (1.6 to 2.0) <0.001
75-79 2.3(2.1 to 2.5) <0.001
80-84 3 (2.7 to 3.3) <0.001
85-89 3.8 (3.5 to 4.2) <0.001
90+ 5.4 (4.9 to 5.9) <0.001
Sex Male 1.0




1 episode 1.2 (1.1 to 1.2) <0.001
2-3 episodes 1.3 (1.3 to 1.3) <0.001
4-7 episodes 1.4(1.4 to 1.5) <0.001








Yes 1.4 (1.4 to 1.5) <0.001
Cancer registration No 1.0
Yes 1.9 (1.9 to 2.0) <0.001
Period of hip fracture 1986 to 1991 1.0
1992 to 1997 0.91 (0.89 to 0.94) <0.001
1998 to 2003 0.87 (0.85 to 0.9) <0.001
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Table 3.6 Number of inpatient episodes in the 5-years prior to hip fracture
admission comparing all SMR patients admitted with hip fracture between
1998 and 2003 with a subgroup of SHFA participants
Comparison of the number of inpatient episodes in the five years prior to hip
fracture admission, for all patients aged 60 years and over admitted with hip
fracture to NHS hospitals in Scotland (SMR) between 1998 and 2003 (n=34012)
and a subgroup of patients participating in the Scottish Hip Fracture Audit
(SHFA) between 1998 and 2003 (n=8470)







Inpatient episodes in the


























Total 34012 100 8470 100
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Table 3.7 Admissions with selected medical diagnoses in the 5-years prior
to the hip fracture admission comparing all SMR patients admitted with
hip fracture between 1998 and 2003 with a subgroup of SHFA participants
Comparison of the proportion of patients admitted with common medical
diagnoses in the five years prior to hip fracture, for all patients aged 60 years
and over admitted with hip fracture to NHS hospitals in Scotland (SMR)
between 1998 and 2003 (n=34012) and a subgroup of patients participating in
the Scottish Hip Fracture Audit (SHFA) between 1998 and 2003 (n=8470).
Source: Scottish Morbidity Records
All hip fracture patients in
SMR database (n=34012)
Patients with complete SMR
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Table 3.8 Primary cause of death in the year following hip fracture for
SHFA participants
Primary cause of death (using groupings based on ICD-10 chapters) for a
subgroup of SHFA participants between 1998 and 2003 (n=2531 deaths/ 8470
participants)
Source: Scottish Morbidity Records (1998 to 2003)
Cause of death Number (%)




Neurological/ Neuropsychiatric 217 (8.6)
Gastrointestinal 87 (3.4)




Other (including iatrogenic) 20 (0.8)
Skin 8 (0.3)
Includes coronary heart disease, stroke, other cardiovascular disease, valvular heart disease
and cardiomyopathy.
* The majority of deaths attributed to trauma are likely to be related to the episode causing the
hip fracture, though a small proportion of patients may have suffered a subsequent trauma
resulting in death.
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Table 3.9 CHD and TED outcomes following hip fracture
Patients with inpatient episodes where the primary diagnosis was recorded as
the conditions listed, in the year following hip fracture admission.
Source: Scottish Morbidity Records
Table 3.9a
Inpatient episodes in the year following hip fracture admission.
SMR extract 1998 to
2003(n=34012)
Patients with complete
SMR and SHFA data
(n=8470)
Inpatient episodes Number % (95% CI) Number % (95% CI)
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Table 3.9b
Deaths in the year following hip fracture admission.
SMR extract 1998 to
2003(n=34012)
Patients with complete
SMR and SHFA data
(n=8470)
Deaths Number % (95% CI) Number % (95% CI)
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4.1 Introduction
The analysis of routinely collected hospital discharge data (chapter 3) has provided
information about previous inpatient episodes with medical diagnoses, and socio¬
economic status. SHFA data are described in this chapter, providing prospectively
collected information unavailable from the SMR database.
4.2 Background
The SHFA started in two pilot hospitals in Scotland in 1992. Based on the Standardised
Audit of Hip Fractures in Europe, the audit collects data about patient circumstances
and quality of care. Typically around half the elderly hip fracture patients admitted with
hip fracture in Scotland are included in the audit, though, as shown in chapter 3 there is
under-representation of patients from more deprived areas.
The main focus of this work is to understand how different types of thrombo¬
prophylaxis have influenced outcomes following hip fracture. The SHFA database
includes information about thromboprophylaxis as well as other factors identified in the
literature review that influence outcome (chapter 2). These include residence and
walking ability prior to hip fracture, and the American Society of Anesthesiologists
(ASA) grade, a measure of physical health prior to fracture (1 = fit, 5 = moribund - see
section 2.5.2.3 for more information). Each of these factors has been shown previously
to be a strong predictor of outcome following hip fracture as described in chapter 2.
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4.3 Rationale
4.3.1 Objective 3a. To use SHFA variables to describe characteristics of
SHFA participants receiving different types of thromboprophylaxis
Many of the potential confounding factors identified in the literature review (chapter 2)
are described in the SHFA database. These potential confounding factors are described
here, dividing the results by the types of thromboprophylaxis administered. These
findings will be used in the final analysis presented in chapter 5.
4.3.2 Objective 3b. To study the association between different types of
thromboprophylaxis and mortality before and after adjusting for
comorbidities and cofactors using SHFA data
SHFA data include outcomes at 120 days. These data are collected by local audit co¬
ordinators, during telephone or face-to-face interviews with the patient or carer. These
outcome data may be more accurate than the linked outcomes used in the analysis
presented in chapter 5. A separate analysis using just SHFA data is therefore presented
in this chapter.
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4.4 Methods
4.4.1 Participants
SHFA data were available for 18267 hip fractures in 17928 patients aged 60 years and
over (339 patients were included twice in SHFA, and the second hip fracture was
excluded for this analysis). For these 17928 patients, a number of exclusions were
necessary: 7640 (42.6%) because there were data missing for one or more SHFA
variable, 525 (2.9%) because they had no information about whether operation was
performed, and 135 (0.7%) because they were recorded as having pathological fracture.
Patients with pathological fracture were excluded because the most likely cause was
cancer that had metastasised to the bone. Hip fracture patients with metastatic cancer
are likely to have a higher mortality rate, a higher incidence of TED, and may be given
different thromboprophylaxis regimes when compared with hip fracture patients in
general.
In order to simplify the presentation of results in this and subsequent chapters, other
patients were excluded following a comparison of SHFA data with SMR data. The
process of linking SHFA and SMR records is described in section 5.4. After comparing
the two databases, 63 (0.3%) patients were excluded because there was a discrepancy
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between SMR and SHFA*, 789 (4.4%) because of uncertainties about the accuracy of
record linkage to an SMR record, and 306 (1.7%) because they did not have a health
board of residence recorded in SMR and did not therefore appear to be resident in
Scotland.
In total, 8470 (47.2%) SHFA participants aged 60 years and over, with hip fracture
admission between 1998 and 2003, were included in the final analysis. SHFA data were
collected separately from SMR data, so it would have been possible to perform the
SHFA analysis without excluding patients identified above for whom there were
uncertainties within the SMR database about record linkage (11=789)* or health board of
residence (n=306)+. However, even using SHFA outcome data exclusively, mortality at
120 days was significantly different for these excluded patients when compared with the
rest of the SHFA patients included in the analysis. Patients without record linkage data
had a death rate at 120 days of 35.0% (95% CI 31.6 to 38.5%), compared to 9.2% (95%
CI 5.7 to 12.7%) for patients without heath board of residence recorded, and 18.9%
Discrepancy of more than one year in age, more than one month for date of hip fracture
admission or date of death, or difference in recorded sex.
* For these patients, the SHFA record had had been linked to a patient record set in SMR01, but
it was not possible to link to a matching admission within that record set.
1 These patients had a lower mortality and a lower rate of hospital episodes both before and
after the index admission with hip fracture. One possible explanation is that while the patient
was admitted to a hospital in Scotland, he or she was not normally resident in Scotland. This
would explain the lack of information about health board of residence, and the lower than
expected hospitalization and mortality rates.
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(95% CI 18.0 to 19.7%) for the patients included in the final analysis (%2 = 132,
p<0.001). It was not possible to corroborate findings between SHFA and SMR
databases or to identify duplicate information for these patients. For these reasons, both
groups have been excluded from further analysis.
Fourteen hospitals participated in the audit during the period of study. The number of
patients contributed by different hospitals varied considerably, reflecting differences in
size and type of hospital. The hospital contributing the smallest number of cases (n=51)
was a district general hospital. Three hospitals contributed over 40% of cases including
in the analysis - a district general hospital in the West of Scotland (n=1298), a large
teaching hospital in the South East of Scotland (n=l 138), and a district general hospital
in the North of Scotland (n=1034).
4.4.2 Ethical and privacy considerations
Participants in the SHFA gave consent to having their data used for audit purposes and
were given the opportunity to opt out from having their data used for research purposes.
The study protocol was agreed by the Privacy Advisory Committee ofNational Services
Scotland. Records were anonymised following record linkage and prior to analysis
(chapter 5).
4.4.3 Data collection
SHFA data were collected at the time of acute hip fracture admission by local audit co-
• 76
ordinators, using forms based on the Standardised Audit of Hip Fractures in Europe .
SHFA data provided pre-fracture status (residence and mobility) and aspects of medical,
surgical and anaesthetic care during the hip fracture admission. Between 1998 and 2003
SHFA forms included detailed information about thromboprophylaxis during the
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hospital admission including up to three types of thromboprophylaxis, the timing of the
first thromboprophylaxis treatment in relation to surgery and the combined duration of
all thromboprophylaxis.
The audit forms were collected centrally at ISD, and inconsistencies in the information
explored further with hospital audit staff before entering data in mutually exclusive
categories into a database.
4.4.4 Data coding
Variables of potential interest that were identified from the literature review were
explored and, for categories with small numbers or redundant information, regrouped
into the categories shown in tables 4.1 and 4.2. Data for age and sex were complete, but
other variables had missing values and there were some ambiguities for some variables.
For example, heparin could be coded as LMWH, heparin - type unspecified, or
conventional heparin. For the latter two categories the type of heparin and route of
administration was not clear. As a result information about heparin was grouped into a
single category. The multivariate analysis described in this chapter and the subsequent
chapter was repeated for LWMH and other types of heparin separately, but this did not
change the findings (results not shown).
Information about timing and duration of thromboprophylaxis was only available for the
period of the index admission, and not for subsequent episodes within the same
continuous inpatient stay. The inability to match information about type, timing and
duration of thromboprophylaxis for patients receiving more than one type of
thromboprophylaxis limits the usefulness of these findings and would have reduced the
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statistical power, so neither variable has been explored further, beyond a basic
description.
4.4.5 Statistical analysis
Statistical analysis was carried out with SPSS (version 11.5) using a number of different
techniques described in chapter 3 (section 3.4.6). Cox proportional hazards regression
analysis was performed using outcome at up to 120 days following hip fracture
admission. Hospital was included as a variable in multivariate analysis, but to simplify
the presentation of results the hazard ratios for individual hospitals are not shown in this
chapter or chapter 5.
Some patients may have died before thromboprophylaxis was administered or had the
chance to take effect, potentially resulting in an under-estimate of the effectiveness of
thromboprophylaxis. To explore this further, patients who died within 5 days of
admission (n=96) were excluded and multivariate analysis repeated.
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4.5 Results
4.5.1 Objective 3a. To describe characteristics of SHFA participants
receiving different types of thromboprophylaxis (n=8470)
The mean age of patients admitted with hip fracture was 81.6 years (95% CI 81.4 to
81.8 years). This analysis has been restricted to the three most commonly used types of
thromboprophylaxis - heparin, GEC stockings and aspirin. For these types of
thromboprophylaxis, 4584 (54.1%) received one type of thromboprophylaxis, 2668
(31.5%) received two types of thromboprophylaxis and 220 (2.6%) received three types
of thromboprophylaxis. The analysis also included 954 (11.3%) patients who were
documented as having received no thromboprophylaxis and 44 (0.5%) patients who
were documented as receiving exclusively warfarin or foot pumps for
thromboprophylaxis*.
Data about the timing of thromboprophylaxis in relation to surgery were available for
7107 (84%) patients. Of these patients, 2678 (38%) received thromboprophylaxis prior
to surgery. The median duration of thromboprophylaxis was 9 days (interquartile range
5-14 days, n=7136). The proportion of patients recorded as receiving different types of
thromboprophylaxis varied between hospitals with ranges of 13 to 96% for heparin, 0 to
In total, 191 (2.3%) patients were documented as having received warfarin and 69 (0.8%)
patients were documented as having received foot pumps.
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84% for GEC stockings, 0.3 to 82% for aspirin, and 0 to 68% received no
thromboprophylaxis.
The characteristics of patients who received either heparin, GEC stockings, and/or
aspirin are shown in tables 4.1 and 4.2. Patients documented as receiving GEC
stockings may have been fitter prior to hip fracture than other patients - they tended to
be younger and were more likely to have lived in their own home pre-fracture. Patients
documented as receiving heparin were also more likely to have lived in their own home
pre-fracture. Patients documented as having received aspirin may have been less fit, as
fewer walked without aids pre-fracture, fewer had favourable ASA grades, and a
slightly higher proportion of men were documented as receiving aspirin than expected
overall. Patients who were documented as having received GEC stockings were more
likely to have also received aspirin, and vice versa. However, patients who received
heparin were less likely to have received either aspirin or stockings.
4.5.2 Objective 3b. To study the association between different types of
thromboprophylaxis and mortality before and after adjusting for
comorbidities and cofactors using SHFA data.
There were 1597 deaths (18.9%, 95% CI 18.0 to 19.7) in the 120 days following hip
fracture admission. The recorded death rate for individual hospitals varied from 13.6%
to 24.2%. Cox proportional hazards regression analysis was used to estimate the risk of
death at 120 days, adjusting for sex, age, residence pre-fracture, walking ability pre-
fracture, ASA grade, fracture type, delay to surgery and prophylaxis (antibiotic or
thromboprophylaxis). Table 4.3 and 4.4 show the results for univariate and multivariate
analysis respectively.
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The results of univariate analysis showed that there were strong relationships between
mortality and the following variables: sex, age, ASA grade, residence and mobility prior
to surgery, delay to surgery for medical reasons, use of antibiotics and
thromboprophylaxis. The Cox model identified in multivariate analysis included each
of these variables apart from mobility prior to surgery and antibiotics.
Aspirin and GEC stockings were associated with a lower mortality in univariate analysis
with hazard ratios of 0.82 (95% CI 0.73 to 0.91) and 0.74 (95% CI 0.66 to 0.82)
respectively. Patients receiving heparin or no thromboprophylaxis had a higher
mortality with hazard ratios of 1.15 (95% CI 1.04 to 1.27) and 1.32 (95% CI 1.15 to
1.52) respectively. However, only aspirin remained in the model in multivariate
analysis with a hazard ratio of 0.81 (95% CI 0.71 to 0.93). The survival function is
plotted in figure 4.1. Excluding patients who died within five days of hospital
admission did not influence the findings (results not shown). However aspirin was no
longer included in the model once interaction terms were included (results not shown).
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4.6 Discussion
There are a number of strengths to this analysis of SHFA data. SHFA data, including
outcomes at 120 days, were collected prospectively by trained audit co-ordinators, using
an internationally recognised audit form designed specifically for the purpose of
documenting information related to the function status, health and management of hip
fracture patients. As a result, the variables available for the analysis were relevant to
hip fracture outcomes, as identified in the literature review (chapter 2). The use of
prospective data collection by trained personnel is likely to have minimised the potential
for bias though there remains the possibility that recording practices varied between
hospitals.
Adjusting for cofactors and comorbidities was important in understanding the potential
influence of thromboprophylaxis on mortality. Some SHFA variables had more of an
influence on the multivariate analysis than others. Mobility prior to fracture and
antibiotic prophylaxis did not influence multivariate analysis and have not therefore
been included in further analysis. For delay to surgery, only delay for medical reasons
had a significant influence on the multivariate model, perhaps explaining the
contradictory findings for studies based on duration of delay rather than cause of
delay43. For fracture type only intertrochanteric fracture had a statistically significant
and detrimental influence, a finding that is consistent with other studies and may be
explained by the increased blood loss observed with extracapsular fractures56 and the
more complex surgical procedures required, including internal fixation.
There are, however, a number of limitations to using SHFA data. A number of
variables, including ASA grade and thromboprophylaxis were incompletely recorded in
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some hospitals, leading to a large number of exclusions as documented in section 4.4.1.
Patients recorded as receiving different types of thromboprophylaxis may not have
received these treatments reliably or consistently. Thus, a patient prescribed aspirin
may not have been well enough to swallow the medication, and a patient prescribed
GEC stockings may not have worn the GEC stockings for the majority of the hospital
admission, whether due to problems fitting the GEC stockings or patient preference*.
Furthermore, the wide range in thromboprophylaxis use between hospitals (section
4.5.1) may reflect differences in recording rather than differences in management
between hospitals. However, where data about thromboprophylaxis were unavailable,
patients were excluded from the analysis. There were no data in SHFA about speed of
mobilisation following hip fracture surgery (see section 2.5.2.4).
There are also potential inconsistencies in the documentation of physical status in
SHFA. ASA grade is the only measure of physical status recorded in SHFA and is
meant to document the presence of serious medical conditions prior to hip fracture.
However, there is evidence from the published literature that some centres use ASA
*
There is some anecdotal evidence for this. Presentation of some early findings from this work
at a national hip fracture conference in 2004 led some nursing staff on orthopaedic wards to
observe that they would not put GEC stockings on a patient, even if recommended by a
consultant, if the patient had poor skin condition or circulation. Others noted that stockings are
sometimes poorly fitted, limiting their usefulness.
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grade as a measure of physical condition during the hospital admission77. IfASA was
used in this way in some centres, then this would lead to an overestimation of ASA
grade, and would result in a biased estimate of the influence of ASA grade on outcome.
However, there is no evidence of overestimation of ASA grade in this current study, as
only 14% of patients were recorded as ASA grades 4 or 5. Additionally, there was an
increase in hazard ratio with increasing ASA grade (tables 4.3 and 4.4).
The results of multivariate analysis presented in table 4.4 show that use of aspirin was
associated with a lower mortality rate following hip fracture. These findings are
consistent with existing guidelines3, which used the findings of the PEP study to
recommend aspirin, though this was based on clinical evidence of TED rather than all-
cause mortality20. Aspirin also has a potentially beneficial influence on cardiovascular
outcomes, breast cancer and colorectal cancer, which are commonly recorded in elderly
hip fracture patients (see section 1.4).
The findings for aspirin may, however, be explained by residual confounding, either due
to factors that were not recorded in SHFA or by factors that were incompletely or
inaccurately recorded in SHFA. The difference in outcome and aspirin usage in
different hospitals provides one potential source of confounding. However, hospital
was included as a variable in the multivariate analysis which should have minimised
this influence. The lack of high quality and unambiguous information about physical
health provides another potential source of confounding and there therefore remains the
possibility that frailer and/or sicker patients were underrepresented in the group
documented as receiving aspirin.
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Heparin did not appear to have a statistically significant influence on mortality, in
apparent contradiction to advice in the guidlines5'17'48. A potential explanation for this
finding is that heparin might increase serious haemorrhage following surgery, but the
Cochrane review of thromboprophylaxis suggests that this is not the case19.
Finally, there remains the possibility that a substantial proportion of patients died before
thromboprophylaxis had a chance to take effect. If this was the case, then there would
be a strong case for excluding these patients from the analysis. Indeed, when the
analysis was repeated after excluding patients who had died within 5 days of hospital
admission, the apparently protective influence of aspirin on survival persisted.
4.7 Conclusions
There is evidence, using SHFA data, of a protective influence of aspirin on all-cause
mortality in the first 120 days following hip fracture admission. This analysis has
shown some of the strengths and limitations of using SHFA data. Some variables were
missing or the information recorded was potentially ambiguous, while others did not
appear to influence the findings of the analysis. These findings have been used in the
design of the study described in the next chapter. The findings may be explained by
residual confounding, particularly relating to the physical status of hip fracture patients,
a possibility that is explored using more detailed information about physical health in
the following chapter.
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4.8 Figures and tables
Figure 4.1 Cox proportional hazards survival functions for aspirin / no
aspirin using SHFA data
Figure 4.1a shows the Cox proportion hazards survival functions (plotted at
mean of covariates) for aspirin, based on the Cox proportional hazards
regression model shown in table 4.4. Figure 4.1b shows the log minus log
curves used to test the assumption of proportional hazards.
n=8470
Source: SHFA (1998 to 2003)
Figure 4.1a
Cox proportional hazards survival functions, plotted at the mean
of covariates, for patients documented as receiving aspirin
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Figure 4.1b
Log minus log curves, testing for the assumption of proportional
hazards. The curves run closely parallel, suggesting that this
assumption is justified.
o
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Table 4.3 Results of univariate Cox proportional hazards regression
analysis describing the association between key SHFA variables and
mortality in the 120 days following hip fracture admission
n=8470
Source: SHFA (1998 to 2003)
Variable Category Hazard ratio
(95% CI) p value
Sex Male 1.00
Female 0.56 (0.51 to 0.63) <0.001
Age (years) 60-69 1.00
70-74 1.93 (1.37 to 2.72) 0.001
75-79 2.19(1.60 to 3.02) <0.001
80-84 3.22 (2.37 to 4.37) <0.001
85-89 4.24 (3.14 to 5.72) <0.001
90+ 5.41 (4.00 to 7.31) <0.001
Residence pre
fracture
Own home or sheltered housing 1.00




Walked with aids 1.59(1.43 to 1.76) <0.001
Bed/ chair bound 2.42(1.86 to 3.16) <0.001
ASA grade ASA grades 1-2 1.00
ASA grade 3 2.57 (2.23 to 2.96) <0.001
ASA grades 4-5 5.42 (4.63 to 6.35) <0.001
Fracture type Displaced capsular 1.00
Undisplaced intracapsular 0.78 (0.64 to 0.94) 0.01
Basocervical 1.27 (1.01 to 1.59) 0.04
Intertrochanteric (2 fragments) 1.16(1.03 to 1.31) 0.02
Intertrochanteric (>2 frags) 1.36 (1.18 to 1.57) <0.001
Subtrochanteric 1.21 (0.91 to 1.61) 0.2
Pressure sores Present pre fracture 1.52 (1.36 to 1.69) <0.001
Delay to surgery No delay 1.00
Administrative delay 0.96 (0.83 to 1.11) 0.6
Patient medically unfit 1.85 (1.64 to 2.09) <0.001
Other reason for delay 1.29 (1.07 to 1.55) 0.008
Prophylaxis Antibiotics 1.19 (1.02 to 1.39) 0.02
Aspirin 0.82 (0.73 to 0.91 <0.001
Heparin 1.15(1.04 to 1.27) 0.005
GEC stockings 0.74 (0.66 to 0.82) <0.001
No thromboprophylaxis 1.32 (1.15 to 1.52) <0.001
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Table 4.4 Results of multivariate Cox proportional hazards regression
analysis describing the association between key SHFA variables and
mortality in the 120 days following hip fracture admission
n=8470
Hospital was also included in the analysis but the results are not shown.
Source: SHFA (1998 to 2003)
Variable Category HR (95% CI) p value
Sex Female 0.50 (0.45 to 0.56) <0.001
Age 70-74 1.78 (1.26 to 2.51) 0.001
75-79 2.01 (1.46 to 2.77) <0.001
80-84 2.87 (2.11 to 3.90) <0.001
85-89 3.56 (2.63 to 4.83) <0.001
90+ 4.21 (3.10 to 5.72) <0.001
Residence Residential care or other
hospital setting
1.90 (1.71 to 2.11) <0.001
ASA grade ASA grade 3 2.00 (1.73 to 2.31) <0.001
ASA grades 4-5 3.63 (3.06 to 4.31) <0.001
Fracture type Displaced capsular
Undisplaced intracapsular 0.88 (0.72 to 1.07) 0.2
Basocervical 1.12 (0.90 to 1.41) 0.3
Intertrochanteric (2 fragments) 1.06 (0.94 to 1.20) 0.3
Intertrochanteric
(multifragment)
1.33 (1.15 to 1.54) <0.001
Subtrochanteric 1.16 (0.87 to 1.55) 0.3
Pressure sores Present prior to surgery 1.32 (1.17 to 1.50) <0.001
Delay to surgery Administrative delay 0.90 (0.77 to 1.05) 0.2
Medically unfit 1.35 (1.18 to 1.53) <0.001
Other 1.09 (0.90 to 1.32) 0.4
Thrombo¬
prophylaxis
Aspirin 0.81 (0.71 to 0.92) 0.002
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5 SHFA-SMR linked database 1998-2003
5.1 Introduction
Using SHFA data, the results set out in the previous chapter suggested that use of
aspirin as thromboprophylaxis may reduce mortality in the first four months following
admission with hip fracture. Additional information is available from the SMR
database as described in chapter 3, and SHFA and SMR records have been linked to
provide a more detailed analysis.
5.2 Background
Previous chapters have set the context and described the methodology used in this
chapter. The importance of adjusting for various cofactors and comorbidities was
highlighted in the literature review (chapter 2). The options for studying these cofactors
and comorbidities have been discussed in chapters describing SMR (chapter 3) and
SHFA (chapter 4). The principals behind record linkage are described in chapter 3.
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5.3 Rationale
5.3.1 Objective 4a. To describe relevant SMR variables for SHFA
participants receiving different types of thromboprophylaxis
The characteristics of patients receiving different types of thromboprophylaxis have
been described for SHFA variables (chapter 4). Linked SHFA-SMR data offer the
opportunity to combine the detailed information relevant to hip fracture and short term
(120 day) follow-up data from SHFA with comorbidity, socio-economic status and
long-term follow-up data available through SMR.
5.3.2 Objective 4b. To study the association between different types of
thromboprophylaxis and mortality before and after adjusting for
comorbidities and cofactors
The literature review has identified a need for more evidence relating to the influence of
different types of thromboprophylaxis on long-term survival following hip fracture. The
influence of thromboprophylaxis on mortality during the year following hip fracture is
assessed using the linked SHFA-SMR database.
5.3.3 Objective 4c. To study the association between different types of
thromboprophylaxis and secondary endpoint before and after
adjusting for comorbidities and cofactors
There is evidence using SHFA data of a survival benefit over 120 day follow-up with
aspirin (chapter 4). The proposed mechanism is through a reduction in TED and CHD.
The influence of thromboprophylaxis on combined inpatient episodes or deaths from
TED or CHD over a one year period is studied, adjusting for the cofactors and
comorbidities identified in preceding chapters.
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5.4 Methods
Analysis was performed using the approaches already described in chapters 3 and 4.
The categories selected for the analysis (listed in tables 5.1 and 5.2) were based on the
findings of the two previous chapters. The index admission was identified from SHFA,
and the SHFA record linked to SMR records using probability matching, as described in
section 3.4.4. The SMR record identified by record linkage had to be related to hip
fracture (ICD-10 codes S70-79) and had to occur within one month of the SHFA record.
Complete data were identified for 8470 SHFA participants (section 4.4.1).
Cox proportional hazards regression analysis was performed using the forward
conditional method, as described in chapter 3, but using all-cause mortality (primary
endpoint) and deaths or inpatient episodes with TED or CHD (secondary endpoint)
during the year following hip fracture admission. Tests for interactions between
variables included in the Cox analysis were undertaken. The analysis was repeated after
excluding patients who died within 5 days of hip fracture admission to explore the
possibility that patients may have died before thromboprophylaxis was administered or
had a chance to take effect (see section 4.4.5).
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5.5 Results
5.5.1 Objective 4a. To describe relevant SMR variables for SHFA
participants receiving different types of thromboprophylaxis
(n=8470)
Overall 6495 (76.7%) patients had been admitted to hospital at least once in the five
years prior to the hip fracture admission. Details of these inpatient episodes are shown
in table 5.1, dividing results for patients documented as having received aspirin,
heparin, GEC stockings or no thromboprophylaxis. Patients with previous inpatient
episodes with CVD were more likely to be documented as having received aspirin
during the hip fracture admission, while the reverse was true for patients with previous
inpatient episodes with respiratory disease. Patients with previous inpatient episodes
with respiratory disease were more likely to receive heparin during the hospital
admission. Patients with no previous hospital inpatient episodes in the previous five
years were less likely to be documented as having received aspirin during the hip
fracture admission but were more likely to be documented as having received heparin.
The median length of the hip fracture admission recorded in the SHFA-SMR database
was 23 days (interquartile range 11 to 49 days).
5.5.2 Objective 4b. To study the association between different types of
thromboprophylaxis and mortality before and after adjusting for
comorbidities and cofactors (n=8470)
There were 2531 deaths in the year following hip fracture admission (29.9%; 95% CI
28.9 to 30.9%). Results of univariate analysis for the association of SHFA variables
with all-cause mortality are shown in table 5.2. Mortality at one year was associated
strongly with age, residence, ASA grade, intertrochanteric fracture, pressure sores, and
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delay for medical reasons. For SMR variables (table 5.3), mortality at one year was
associated strongly with the number of previous inpatient episodes, previous inpatient
episodes with CVD or respiratory disease and documentation of cancer registration.
There was no apparent association however between mortality and the Scottish Index of
Multiple Deprivation.
Both aspirin and GEC stockings were associated with lower mortality in univariate
analysis and multivariate analysis. Compared to the results of univariate analysis,
however, adjusting for cofactors in multivariate analysis attenuated the apparent
protective effect of GEC stockings (HR increased from 0.80 to 0.88) and amplified the
apparent protective effect of aspirin (HR decreased from 0.92 to 0.86). The findings
persisted after interaction terms* were included in the model. After repeating the
analysis to exclude patients who died in the first 5 days following hip fracture, however,
neither the association between aspirin nor GEC stockings and mortality remained
statistically significant.
*
There were statistically significant interactions between age category and each of the
following: ASA grade, no thromboprophylaxis and cancer registration. There were also
statistically significant interactions between number of inpatient episodes in the 5-years prior to
hip fracture admission and documentation of previous inpatients episodes with CVD or cancer
registration.
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5.5.3 Objective 4c. To study the association between different types of
thromboprophylaxis and the secondary endpoint before and after
adjusting for comorbidities and cofactors (n=8470)
As described in section 3.5.3, 275 (3.3%; 95% CI 2.8 to 3.6%) patients had at least one
inpatient episode attributed to CHD/ TED and 422 (5.0%; 95% CI 4.5 to 5.4%) patients
had the primary cause of death recorded as CHD and/ or TED in the year following hip
fracture. In total 628 (7.4%; 95% CI 6.9 to 7.8%) patients had the secondary endpoint
recorded in SMR in the year following hip fracture admission. Figure 5.1 shows Kaplan
Meier curves for inpatient episodes and deaths in the year following hip fracture
recorded as being due to TED or CHD, while figure 5.2 shows the Kaplan Meier curve
for all-cause mortality. The highest event rate (deaths or inpatient episodes) was in the
period immediately after hip fracture admission. The rate of inpatient episodes due to
CHD or TED fell following discharge from hospital as indicated by the sharp fall in the
gradient of the curve for inpatient episodes with CHD or TED in figure 5.1. No
equivalent fall in gradient was observed for deaths from CHD or TED or all-cause
mortality (figure 5.2).
Using Cox proportional hazards regression analysis there was no statistically significant
influence of either aspirin, heparin, GEC stockings or receiving no thromboprophylaxis
on the secondary endpoint within one year of hip fracture admission, using either
univariate or multivariate analysis (results not shown).
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5.6 Discussion
The analysis presented in this chapter has a number of factors in common with the
analysis presented in chapter 4. Both analyses used Cox proportional hazards
regression analysis and both used the same number of SHFA participants. There were,
however some important differences between the analyses. The linked SHFA-SMR
database provided information about previous inpatient episodes and cancer
registrations, and provided information about both primary and secondary endpoints for
a whole year following the hip fracture admission. However the outcomes in the
SHFA-SMR analysis were based on retrospective identification using record linkage
whereas the SHFA data were collected prospectively and may therefore have been more
accurate.
The number of previous inpatient episodes, previous inpatient episodes with CVD or
respiratory disease and cancer registration had an important influence on univariate
analysis (table 5.3) and multivariate analysis (table 5.4). However, in multivariate
analysis the hazard ratio for previous inpatient episodes with CVD was only modestly
increased at 1.14 (95% CI 1.04 to 1.25) and was lower than previous inpatient episodes
with respiratory disease (HR 1.28; 95% CI 1.14 to 1.44) and registration with cancer
(HR 1.74; 95% CI 1.49 to 2.04). The lower than expected association between CVD
and mortality is consistent with the findings of the recent study by Roche et al discussed
in section 2.747.
Socio-economic status, measured by SIMD, did not have an independent effect on
mortality in multivariate analyses. The absence of an influence with SIMD may be
explained in two ways. First, the estimate of SIMD for an area may not have accurately
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reflected the socio-economic status of hip fracture patients living in that area as hip
fracture patients are typically elderly, retired, may be socially isolated and commonly
have high levels of dependency and medical illness. Secondly, socio-economic status
may have influenced the Cox regression models through other variables including the
number of previous inpatient episodes and the type of medical conditions, hence
masking the influence of SIMD on mortality. The former explanation appears to be the
most likely, as death rates following hip fracture in more deprived areas were not
significantly higher than more affluent areas in univariate analysis.
This analysis, using SHFA-SMR linked data, suggests that aspirin and GEC stockings
are associated with lower mortality following hip fracture. This finding is independent
of potential confounding factors recorded in the SMR and SHFA databases. Heparin
did not have a statistically significant influence on mortality. The findings for aspirin
and heparin are consistent with those presented in chapter 4. The finding that GEC
stockings had a statistically significant protective effect was not observed in the analysis
of SHFA data alone, but may be explained by the higher event rate during the longer
period of follow up using linked SHFA-SMR data, resulting in greater statistical power.
The apparent protective effect observed with GEC stockings demonstrated in the linked
SHFA-SMR data provides evidence for an intervention that has been little studied to
date (as noted in systematic reviews and guidelines19), but would be consistent with the
findings of a meta-analysis of studies of general surgery, though these studies used TED
• 1 o
as the endpoint rather than all-cause mortality .
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There may be other explanations for the apparent protective effect of aspirin and/or
GEC stockings. In common with the analysis presented in chapter 4, the findings may
be explained by residual confounding. Patients who received GEC stockings were
younger and had better functioning prior to hip fracture (table 4.1), explaining why the
apparent protective effect of GEC stockings was attenuated in multivariate analysis.
However, patients documented as receiving GEC stockings may have been fitter in
other ways that were not measured in the SHFA or SMR databases - for example,
patients may not have received GEC stockings if they had leg swelling or poor skin
condition, factors that may be associated with unfavourable states including heart
failure, prolonged immobility, peripheral vascular disease or systemic steroid treatment.
However, in one recent study of the elderly hip fracture population in the UK only 2%
of patients received steroids47.
Patients documented as receiving aspirin may have been at higher risk than other
patients, with a higher proportion of patients documented with previous inpatient
episodes due to CVD, but as discussed on page 107 the opposite may also be true.
Indeed, patients documented as taking aspirin were less likely to have documentation of
respiratory disease or cancer (table 5.1).
The reliance on SMR data to identify patients with pre-existing CVD is a potential
source of bias. It is possible, for example, that patients with severe pre-existing CVD
would have been less likely to have been admitted to hospital with CVD if they were
elderly or had inoperable disease, and as a result these patients could be
underrepresented in SMR data. Younger and fitter patients and those with first onset of
symptoms of CVD may have been more likely to have been admitted to hospital for
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investigation and treatment (including revascularisation) and this group may have had a
better prognosis following hip fracture surgery.
Despite the apparent reduction in mortality with GEC stockings and aspirin there was
no evidence of a reduction in the secondary endpoint of combined deaths or inpatient
episodes from TED or CHD with use of thromboprophylaxis. This is in contrast to
other studies, which have typically identified an influence of thromboprophylaxis on
TED but not all-cause mortality (chapter 2). If the apparent protective influence of
aspirin and/or GEC stockings on all-cause mortality was spurious, then no influence on
the secondary endpoint would be expected. However, there remains the possibility that
different diagnoses recorded for the secondary endpoint were inaccurately or
incompletely recorded, so the potential impact of thromboprophylaxis was
underestimated. Figure 5.1 provides some evidence for this: while the incidence and
detection of CHD and TED is likely to have been highest during the period immediately
following hip fracture, there was a noticeable reduction in inpatient episodes due to
TED or CHD following discharge from hospital. This suggests either that there was a
lower detection rate of these complications in the community, or that patients were
being managed in primary care without being admitted to hospital. Deaths recorded in
SMR as being caused by TED or CHD may also have had inaccuracies. Myocardial
infarction is a common cause of death in Scotland, and it may have been documented as
the cause of death where no further exploration of cause was undertaken (the autopsy
rate during the period of study was around 6% of deaths). These points provide further
evidence of the challenges in dealing with routinely collected data.
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5.7 Conclusions
This analysis of the linked SHFA-SMR database provides further evidence that aspirin
may protect against all-cause mortality and also provides evidence of a survival benefit
with GEC stockings. There were, however, some potential sources of bias and
confounding. A randomised controlled trial would be necessary to explore the apparent
protective influence of aspirin and GEC stockings further.
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5.8 Figures and tables
Figure 5.1 Kaplan Meier curves for inpatient episodes and deaths with
CHD/TED in the year following hip fracture
The dotted line shows the median length of hospital stay (23 days)
n=8470 with 275 inpatient episodes and 422 deaths attributed to CHD or TED
Source: SHFA-SMR linked database (1998 to 2003)
Days after hip fracture admission
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Figure 5.2 Kaplan Meier curves for all cause mortality in the year following
hip fracture
The dotted line shows the median length of hospital stay (23 days)
n=8470, with 2531 deaths from all causes
Source: SHFA-SMR linked database (1998 to 2003)
Days after hip fracture admission
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Table 5.2 Univariate analyses describing the association between key
SHFA variables and mortality in the year following hip fracture
Source: SHFA-SMR linked database (1998 to 2003)




Female 0.59 (0.54 to 0.65) <0.001
Age (years) 60-69 1.00
70-74 1.45 (1.14 to 1.85) 0.003
75-79 1.68 (1.35 to 2.09) <0.001
80-84 2.41 (1.95 to 2.97) <0.001
85-89 3.13(2.55 to 3.85) <0.001
90+ 4.00 (3.26 to 4.93) <0.001
Residence prior to
hip fracture
Own home or sheltered
housing 1.00
Residential care or other
hospital 2.54 (2.35 to 2.75) <0.001
ASA grade ASA grades 1-2 1.00
ASA grade 3 2.31 (2.08 to 2.57) <0.001




Yes 1.20 (1.11 to 1.30) <0.001
Delay to surgery
No 1.00




Yes 1.51 (1.39 to 1.65) <0.001
Prophylaxis Heparin 1.05 (0.97 to 1.13) 0.3
GEC stockings 0.80 (0.74 to 0.87) <0.001
Aspirin 0.92 (0.84 to 1.00 0.04
No thromboprophylaxis 1.24 (1.10 to 1.39 <0.001
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Table 5.3 Univariate analysis describing the association between key SMR
variables and mortality in the year following hip fracture
Source: SHFA-SMR linked database (1998 to 2003)
Variable Category Hazard ratio
(95% CI)
p value
Inpatient episodes in the 5
years prior to hip fracture
admission
None 1.00
1 episode 1.40 (1.22 to 1.62) <0.001
2-3 episodes 1.79 (1.57 to 2.02) <0.001
4-7 episodes 2.16(1.90 to 2.45) <0.001








Yes 1.84 (1.65 to 2.05) <0.001
Cancer registration No 1.00
Yes 1.82(1.56 to 2.12) <0.001
Scottish Index of Multiple
Deprivation
Deciles 1-5 1.00
Deciles 6-10 0.95 (0.88 to 1.03) 0.2
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Table 5.4 Multivariate analysis looking at the association between key
SHFA and SMR variables and mortality in the year following hip fracture
The analysis included each of the variables listed in tables 5.2 and 5.3, but the
model included only those identified as being statistically significant using the
forward conditional method. Hospital was also included (data are not shown).
Source: SHFA-SMR linked database (1998 to 2003)
Variable Category HR (95% CI) p value
Sex Male 1.00
Female 0.55 (0.50 to 0.60) <0.001
Age 60 to 69 years 1.00
70 to 74 years 1.37 (1.07 to 1.75) 0.01
75 to 79 years 1.54 (1.24 to 1.93) <0.001
80 to 84 years 2.22 (1.79 to 2.74) <0.001
85 to 89 years 2.76 (2.24 to 3.40) <0.001
90+ years 3.30 (2.66 to 4.08) <0.001
Pre-fracture residence Own home or
sheltered housing 1.00
Nursing home or
other hospital 1.77 (1.63 to 1.93) <0.001
ASA grade ASA grade 1-2 1.00
ASA grade 3 1.72 (1.54 to 1.92) <0.001
ASA grade 4-5 2.83 (2.47 to 3.24) <0.001
Pressure sores prior to
surgery
No 1.00




Yes 1.27 (1.15 to 1.41) <0.001
Number of inpatient
episodes prior to hip
fracture
None 1.00
1 episode 1.16 (1.00 to 1.34) 0.05
2-3 episodes 1.19 (1.04 to 1.35) 0.01
4-7 episodes 1.26 (1.10 to 1.45) 0.001








Yes 1.28 (1.14 to 1.44) <0.001
Cancer registration No 1.00
Yes 1.74(1.49 to 2.04) <0.001
Thromboprophylaxis GEC stockings 0.88 (0.80 to 0.97) 0.01






This chapter brings together the findings of the literature review (chapter 2) and the
results of SHFA and SMR databases (chapters 3 to 5) to answer the research questions
identified in chapter l. The plausibility of the findings is explored by considering the
pathogenesis of TED and the wider effects of different types of thromboprophylaxis.
Finally, recommendations for further research are made based on the findings of this
work.
6.2 Background
Studies based on radiological and/or autopsy findings suggest that TED is common
following hip fracture, as highlighted in guidelines internationally3,5. Unfortunately,
however, there have been no large long-term follow up studies of hip fracture patients
that adequately document TED in the modem era of hip fracture treatment (see
objective la, chapter 2). Additionally, there remains uncertainty about the influence of
thromboprophylaxis on all-cause mortality following hip fracture (see objective lc,
chapter 2). Scottish data (chapters 3 to 5) may provide information about the
epidemiology of TED and effectiveness of thromboprophylaxis that is not available




6.3.1 Question 1. What is the likely burden of TED following hip fracture?
Two studies identified in the literature review provided information about the long-term
incidence of TED following hip fracture. Between 2 and 3% of hip fracture patients
developed clinical PE in the year following hip fracture, but the overall burden of TED
was not documented (section 2.5.1.1). Chapter 3 provides data about the proportion of
patients developing TED following hip fracture in Scotland using SMR data (table 3.9),
and figure 5.1 shows the timing of these events in relation to the date of the hip fracture
admission. Almost 90% of patients included in the analysis presented in chapters 4 and
5 were documented as having received thromboprophylaxis but information about
radiological testing was not available.
The incidence of pulmonary embolism following hip fracture identified using SMR data
was lower than previous studies. The difference, however, is as likely to be explained
by the reliance on routinely collected hospital discharge data as by differences in the
incidence of TED (see section 5.6). Overall, findings from the published literature
(chapter 2) and SMR data (chapter 3) suggest that clinically identified TED is
uncommon in the year following hip fracture. Elowever, the estimated incidence of
clinical TED identified in the literature review and from SMR data do not necessarily
accurately estimate the overall burden of TED and it remains possible that there is a
high incidence of undetected TED contributing to morbidity and mortality following hip
fracture, which would be consistent with the findings of studies based on radiological or
autopsy findings (section 2.5.1.5).
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There is therefore an unresolved paradox in the study of TED following hip fracture.
Studies based on clinical findings are likely to underestimate the burden of clinically
relevant TED, regardless of the use of radiological investigation to confirm the
diagnosis. In contrast, studies based purely on radiological findings or autopsy
examination are likely to overestimate the burden of clinically relevant TED as
autopsies are likely to be performed on an unrepresentative sub-group of the population.
The burden of TED following hip fracture is therefore unclear, particularly in the era of
widespread thromboprophylaxis, and this research question is unlikely to be answered
satisfactorily using existing methods of investigation.
6.3.2 Question 2. Did outcomes in hip fracture patients alter following
the launch of the first national evidence-based guidelines in 1997?
Trends in hip fracture mortality between 1986 and 2003 provide some information with
which to answer this research question (objective 2b). Compared to patients admitted
with hip fracture between 1986 and 1991, patients admitted between 1998 and 2003 had
a lower mortality at one year (hazard ratio 0.87; 95% CI 0.85 to 0.90, p<0.001). It is
not possible, however, to prove that the guidelines, and specifically the advice about
thromboprophylaxis, have led to the apparent reduction in mortality. There remains the
possibility that the findings may be explained by residual confounding, a potential
drawback of all epidemiological research and one that limits any further interpretation
of these data. More sophisticated approaches are therefore required to study the effect
of thromboprophylaxis on mortality, as described below.
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6.3.3 Question 3. Is there evidence of improved survival in hip fracture
patients who have received different types of thromboprophylaxis,
and does this relationship persist after adjusting for cofactors?
This study provides evidence for a protective effect of aspirin (chapters 4 and 5) and
GEC stockings (chapter 5), before and after adjusting for cofactors. There was no
evidence of a protective effect of heparin (chapters 4 and 5) and this remained the case
when the analysis was repeated for LMWH (results not shown). Each of these findings
may however be explained by residual confounding. The plausibility of these findings
is explored in section 6.4.
The apparent protective effect of aspirin and GEC stockings following hip fracture is a
potentially important finding. Each year in Scotland there are around 5,700 hip
fractures in patients aged 60 years and over (section 1.2). Approximately 1710 (30%)
of these patients would be expected to die in the first year following hip fracture
admission (section 5.5.2). The findings of this study suggest that use of GEC stockings
or aspirin could reduce mortality by 12% and 14% respectively (table 5.4). If the
estimated 44% of hip fracture patients* who do not currently receive GEC stockings or
See table 4.2. Of the 8470 SHFA participants included in the analysis 2029 (24%) were
documented as receiving GEC stockings, 1446 (17%) were documented as receiving aspirin
and 1289 (15%) were documented as receiving both GEC stockings and aspirin. Overall 4764




aspirin were to be treated with these types of thromboprophylaxis, then the additional
number of deaths prevented in the year following hip fracture in Scotland is estimated at
90 (for GEC stockings) and 105 (for aspirin).
6.3.4 Question 4. If a particular type of thromboprophylaxis has an
influence on survival, then is this relationship explained by changes
in the incidence of secondary outcomes following hip fracture
(thromboembolic disease, CVD and haemorrhage)?
As explained in section 2.9, the analysis of secondary outcomes focused on CHD rather
than CVD and did not include haemorrhagic events. Despite an apparent reduction in
mortality with GEC stockings and/or aspirin following hip fracture there was no
detectable influence of GEC stockings and/or aspirin on combined TED and CHD
following hip fracture. There are a number of possible explanations for the lack of an
apparent reduction in the secondary endpoint with different types of
thromboprophylaxis, particularly relating to the reliance on hospital discharge data
(section 5.6).
6.3.5 Question 5. How representative of elderly hip fracture patients were
the patients included in this analysis?
The results presented in section 3.5.3 suggest that the group of SHFA participants
included in this study were very similar to the general population of hip fracture patients
aged 60 years and over in Scotland. Although there were differences between the
groups, these were minor and the groups were similar in terms of age, sex, prevalence of
comorbidities and mortality. More important differences were identified for socio¬
economic class, with an under-representation of patients from more deprived areas. This
may not be a major limitation given the observed lack of association between
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deprivation and mortality following fracture. Overall however, with certain caveats, the
findings of this study can be generalised to the general population of hip fracture
patients in Scotland aged 60 years and over.
The findings of this study are likely to be more representative of the general elderly hip
fracture patients than many other studies. In the literature review (chapter 2) for
example, patients with severe systemic illness were excluded from some studies, and
some studies excluded patients with prior TED or very elderly patients. The mortality
rate in some studies was much lower than expected, and the median mortality at a year
in the studies identified at stage 6 of the literature review (figure 2.1) was 20%, much
lower than that expected from Scottish data (30%) . The paper by Roche et al was one
recent exception, recording a mortality rate of 33% at one year47.
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6.4 Plausibility of the findings
There are insufficient data from randomised controlled trials to assess the plausibility of
the findings of this study. The Cochrane review of thromboprophylaxis in hip fracture
patients identified no adequately powered studies of mechanical methods of
thromboprophylaxis including stockings19, and the most recent SIGN guideline on hip
fracture states that there is "no evidence for [the use of graduated elasticated support
• •• t . . ..
stockings] in hip fracture patients" despite evidence suggesting a reduction in TED
associated with their use in patients undergoing general surgery13. While low dose
aspirin is recommended in the SIGN guideline for hip fracture3, this guidance was based
on the PEP trial which identified a reduction in clinical TED rather than all-cause
mortality20. Much of the existing trial evidence for thromboprophylaxis in hip fracture
relates to the use of different types of heparin, studying clinical and radiological TED
rather than mortality. There is evidence of publication bias in the limited number of
studies that have studied the influence of heparin on mortality following hip fracture
(section 2.5.3).
The plausibility of the findings of this study can, however, be explored further by
considering the pathogenesis of TED. Virchow proposed that TED was the result of a
triad of factors: vascular endothelial damage, stasis of blood flow, and
hypercoagulability of blood6, each of which occur in the natural history of hip fracture,
whether during the initial trauma surgical repair, or recuperation period (section 1.3).
In theory, different types of thromboprophylaxis could have an influence on Virchow's
triad and therefore potentially reduce the burden of fatal and non-fatal TED and CHD.
Aspirin and heparin may influence endothelial function and the hypercoagulability of
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blood, thereby increasing vascular flow in veins and arteries. The same is true of more
• • • • 78
modem treatments including the novel pentasaccharide/ heparinoid fondaparinux .
GEC stockings and other mechanical forms of thromboprophylaxis increase venous
flow and this might have an indirect influence on clotting factors and vascular
distension, and may reduce endothelial dysfunction as a result48. However, each of
these interventions act on thrombus formation and development, but do not actively
break down clot that has already formed (thrombolysis)79, so some TED would be
expected even in patients receiving these treatments.
It is possible, therefore, that GEC stockings and aspirin could reduce TED, but whether
they could plausibly cause a reduction in mortality of the magnitude observed in this
study is less clear. Aspirin has the advantage that it may be taken long-term, potentially
reducing TED and CHD in the elderly population at greatest risk of hip fracture. GEC
stockings have the advantage that they do not increase the risk of haemorrhage and may
therefore be applied more readily prior to surgery with a resultant reduction in mortality
peri-operatively and immediately post-operatively, the period during which most
pulmonary emboli occur. However there is no guarantee that stockings are worn
properly for the intended period, and there is some anecdotal evidence that they can be
poorly fitted and poorly tolerated, reducing compliance and the effectiveness of
treatment3. A recent qualitative study showed that in palliative care, patients prefer
• 80 • •
LMWH to GEC stockings . There are also potential explanations for the apparent lack
of a treatment effect with heparin. Heparin may not be administered pre-operatively
because of concerns about haemorrhage and it is not routinely administered long-term
as it is a parenteral treatment.
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6.5 Implications for future research
This study has illustrated how little is known about interventions that may reduce
mortality following hip fracture. Despite many hundreds of randomised controlled
trials, dozens of systematic reviews, meta-analyses, and evidence-based guidelines,
there remain many inconsistencies in the evidence and gaps in our knowledge of this
topic. Indeed many studies included in evidence-based guidelines are now largely of
historical interest only as they were conducted in the period before techniques available
in modern hip fracture management were commonly available. Hip fracture remains a
common condition with a poor prognosis (excess mortality 10 to 20% in the first year
following hip fracture compared to an age and sex matched population1) so it remains
important that these unanswered questions are considered further. Deaths attributed to
diseases of the heart or circulation were twice as common in the year following hip
fracture admission as deaths attributed to trauma (table 3.8) highlighting the potential
importance of medical treatment in hip fracture patients.
This study demonstrates that epidemiological research has an important place in
generating and testing hypotheses. However, there is limited potential for further record
linkage to study thromboprophylaxis in hip fracture patients in more detail using
epidemiological methods. Thromboprophylaxis is no longer adequately documented in
the SHFA (since 2004). While there are moves to link SMR records to prescribing data
this would only provide limited additional information for hip fracture as the data relate
only to primary care and would not include information about GEC stockings (which




This work has illustrated the importance of studying mortality rather than surrogate
endpoints, reinforcing points made in the Cochrane review of thromboprophylaxis
following hip fracture19. A reduction in surrogate endpoints such as radiological
findings does not necessarily translate to an improvement in survival. This is
particularly relevant to hip fracture because of the challenges in the identification of
TED. This study suggests that the use of aspirin and GEC stockings after hip fracture
should be studied further. Additionally, neither this study nor the Cochrane review of
thromboprophylaxis in hip fracture19 have been able to identify a survival benefit with
different types of heparin. This is of importance because heparin is commonly used as
thromboprophylaxis (48% of patients in this study). If heparin was proved to be
ineffective in reducing mortality and clinical events following hip fracture, this could
have important implications for health services and for patients. The use of heparin
involves considerable expense to health services, both in prescribing costs (for LMWH)
and in the monitoring required to ensure therapeutic levels (for unfractionated heparin).
Heparin treatment can also be a source of pain for the patient, requiring repeated
injections or intravenous access.
There is therefore an urgent need for an adequately powered randomised control trial
(RCT) looking at the impact of each of these different types of thromboprophylaxis on
mortality following hip fracture. This study is unlikely to be funded by a
pharmaceutical company, so it would depend on support from the Chief Scientist Office
or other public sector funding. Such a study would be a major undertaking. In order to
detect a reduction in mortality of 10% with aspirin or GEC stockings compared to
heparin in the year following hip fracture admission, the minimum estimated sample
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size would be 3,500 participants in each treatment limb (patients would receive aspirin,
GEC stockings or heparin). In order to recruit all these participants (minimum
number^10,500) in Scotland it would be necessary to involve all 15 hospitals
participating in SHFA over a period of three years, but this assumes that all patients
would agree to participate in the study, which is unrealistic. Given these long
timescales and caveats a multicentre international RCT may be more appropriate.
6.6 Proposed research papers resulting from this work
The five research questions addressed above form the focus of a number of research
papers that are being prepared for publication in peer-reviewed medical journals. Table
6.1 summarises the papers in preparation at the time of writing (March 2006).
6.7 Conclusions
This study has shown that routinely collected data linked to other relevant data sources
can be invaluable, not only in generating hypotheses, but also in estimating the size of
treatment effects for therapies and interventions that have, to date, been incompletely
investigated using randomised controlled trials. The findings of this study suggest that
GEC stockings and/or aspirin (but not heparin) may reduce mortality in the year
following hip fracture in patients aged 60 years and over: GEC stockings are estimated
to reduce mortality by 12%, while aspirin is estimated to reduce mortality by 14%.
These findings are in apparent contradiction to international guidelines and the House of
Commons Health Committee report on thromboprophylaxis5'17'48. The findings may,
however, be explained by residual confounding, and adequately powered multi-centre
randomised controlled trials of different types of thromboprophylaxis are necessary to
test this. In the interim, hip fracture patients should continue to receive aspirin as
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thromboprophylaxis, as recommended in the most recent SIGN guideline for hip
fracture3. The findings of this study suggest that these patients should also receive GEC
stockings, a recommendation that is consistent with advice for other types of major
surgery13.
Mortality following hip fracture remains high in the modern era of hip fracture
treatment, and the burden of TED following hip fracture remains uncertain. In the
future, studies should concentrate on all-cause mortality rather than surrogate endpoints
including clinical and radiological evidence of TED. It will not be possible to improve
the survival of hip fracture patients in the future without understanding which
treatments and interventions are most effective at reducing mortality. This applies as
much to existing treatments including heparin, aspirin and GEC stockings as to novel
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8.1 Search strategy (see section 2.4)
8.1.1 MEDLINE
The following search identified descriptive studies for objectives la and lb. The search
for randomised controlled trials used the results of step 51 of the search and limited the
results to the period between 2001 and 2005 (n=86).
Database: Ovid MEDLINE(R) <1966 to November Week 3 2004>
Search Strategy:




5 Venous Thrombosis/ (6707)
6 Thrombolytic Therapy/ (11393)
7 exp Heparin/ (40952)
8 ((venous or vein$l or pulmonary) adj25 (thrombo$ or embol$)).tw. (51311)
9 or/1-8 (142297)
10 exp Hip Fractures/ (10147)
11 ((hip$ or femur$ or femoral$ or trochantS or pertrochantS or intertrochantS or
subtrochant$ or intracapsular or extracapsular) adj5 fracture$).tw. (15538)
12 or/10-11 (18052)
13 and/9,12 (705)
14 randomized controlled trial.pt. (198393)
15 controlled clinical trial.pt. (68298)
16 randomized controlled trials/ (35630)
17 random allocation/ (52749)
18 double-blind method/ (81218)
19 single-blind method/ (8672)
20 14 or 15 or 16 or 17 or 18 or 19 (336624)
21 limit 20 to animal (25726)
22 limit 20 to human (316495)
23 21 and 22 (7668)
24 21 not 23 (18058)
25 20 not 24 (318566)
26 clinical trial.pt. (399808)
27 exp clinical trials/ (162674)




32 exp research design/ (188452)
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33 26 or 27 or 28 or 29 or 30 or 31 or 32 (737686)
34 limit 33 to animal (93078)
35 limit 33 to human (653829)
36 34 and 35 (34437)
37 34 not 36 (58641)
38 33 not 37 (679045)
39 comparative study/ (1178202)
40 exp evaluation studies/ (510452)
41 follo\V-up studies/ (293938)
42 prospective studies/(182927)
43 (controls or prospectivS or volunteer$).tw. (1515193)
44 39 or 40 or 41 or 42 or 43 (3021424)
45 limit 44 to animal (906149)
46 limit 44 to human (2088953)
47 45 and 46 (201490)
48 45 not 47(704659)
49 44 not 48 (2316765)
50 25 or 38 or 49 (2535115)
51 13 and 50 (366)
52 graduated elasticated support stockings.mp. [mp=title, original title, abstract, name of
substance, mesh subject heading] (0)
53 stockings.mp. [mp=title, original title, abstract, name of substance, mesh subject heading]
(838)
54 stockings.mp. (838)
55 compresS.mp. [mp=title, original title, abstract, name of substance, mesh subject heading]
(52211)
56 stockS.mp. [mp=title, original title, abstract, name of substance, mesh subject heading]
(16450)
57 ted.mp. [mp=title, original title, abstract, name of substance, mesh subject heading] (239)
58 aspirin.mp. [mp=title, original title, abstract, name of substance, mesh subject heading]
(33842)
59 exp ASPIRIN/(26196)
60 thromboprophS.mp. [mp=title, original title, abstract, name of substance, mesh subject
heading] (764)
61 warfarin.mp. or WARFARIN/ (10660)
62 heparin.mp. (58231)
63 Dextrans/ or low molecular heparin.mp. (15700)
64 mobili$.mp. (88626)
65 or/52-64 (264660)
66 65 and 12(1672)
67 9 and 12 (705)
68 66 or 67 (2097)
69 68 not 51 (1731)
70 from 69 keep 1-274(274)
71 limit 70 to yr=1990-2005 (269)




The following search identified descriptive studies for objectives la and lb. The search
for randomised controlled trials used the results of step 32 of the search and limited the
results to the period between 2001 and 2005 (n=149).




3 thrombosis/ or deep vein thrombosis/ or leg thrombosis/ or postoperative thrombosis/
(34396)
4 anticoagulant therapy/ or fibrinolytic therapy/ (13814)
5 exp Anticoagulant Agent/ (149160)
6 Heparin/(40514)
7 ((venous or vein$l or pulmonary) adj25 (thromboS or embol$)).tw. (33919)
8 or/1-7 (195176)
9 exp Hip Fracture/ (7087)











21 comparative study.tw. (17061)




26 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 (1973007)
27 human.sh. (3975960)
28 nonhuman.sh. (2008321)
29 27 and 28 (310044)
30 28 not 29 (1698277)
31 26 not 30 (1185495)
32 12 and 31 (247)
33 stockings.mp. or Compression Therapy/ or elastic stockings/ or Leg Compression/ (3131)
34 ted.mp. (243)
35 aspirin.mp. or Acetylsalicylic Acid/ (50317)
36 thromboprophylaxis.mp. or Thrombosis Prevention/ (2118)
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37 thromboproph$.mp. [mp=title, abstract, subject headings, drug trade name, original title,
device manufacturer, drug manufacturer name] (730)
38 warfarin.mp. or WARFARIN/ (18991)
39 low molecular heparin.mp. or Low Molecular Weight Heparin/ (8776)
40 heparin.mp. (51273)
41 DEXTRAN SULFATE/ or DEXTRAN 70/ or DEXTRAN/ or DEXTRAN 60/ or
dextran.mp. or DEXTRAN 40/ or DEXTRAN DERIVATIVE/ (13360)
42 mobiliS.mp. (63349)
43 or/33-42 (179265)
44 43 or 8 (276460)
45 44 and 11 (1125)
46 45 not 32 (878)
47 limit 46 to yr=l 990 - 2005 (847)
48 Breast Cancer/ or Hormone Substitution/ or Estrogen/ or Sex Hormone/ or hrt.mp. or
Estradiol/(125617)
49 47 not 48 (741)
50 from 47 keep 1-10 (10)
51 from 47 keep 1-847(847)
160
